Friday, October 31, 2025
Home Blog Page 4

Ghost Bites (Bytes Technology | CMH | Ninety One | Santova | Tharisa)

The shine has come off Bytes Technology Group in a big way (JSE: BYI)

The company has bigger problems than repairing its reputation after the shocking governance around the ex-CEO’s trades

In February 2024, former Bytes Technology Group CEO Neil Murphy resigned after an astonishing number of undisclosed share trades suddenly came to light. The share price was obliterated in response, with Sam Mudd promoted to CEO shortly after the initial chaos.

The share price bounced back strongly initially, but the unfortunate reality is that the company has much bigger problems than a badly behaved ex-CEO. The UK market hasn’t been great for the past couple of years and Bytes was priced for growth, so a nasty slowdown in performance can only lead to a drop in the share price. With the release of results for the six months to August 2025, the market has been disappointed once more and has shown its displeasure:

The problem seems to primarily lie in the margins. Gross invoiced invoice (GII) might be up 9.1% year-on-year, but revenue is up just 2.5% and gross profit increased by a measly 0.4%. Costs unfortunately didn’t sit still (especially with headcount up 12% year-on-year), so operating profit dropped by 7% and operating margin dipped from 43.4% to 40.2%. By the time you get to HEPS, the decrease is 5.1%.

There clearly aren’t many highlights here. A slightly silver lining is growth in the interim dividend per share of 3.2%, although this isn’t a sustainable trajectory unless earnings improve. The board’s confidence to increase the dividend would’ve come from a 15.1% increase in cash on the balance sheet.

The problem is that Bytes doesn’t really have a moat. They are selling products on behalf of the likes of Microsoft, so a change to how Microsoft incentivises its partners can cause considerable pain. This is why the company is focusing on services vs. software, as it gives them more control over their margins. That strategy is bearing fruit, with software GII up 8.9% and services GII up 15.1%. But what investors really want to see is an uptick in revenue and margins, as that’s what counts.

It’s unlikely that the trajectory will be any prettier in the second half of the year, as they are up against a particularly strong base period.


Combined Motor Holdings gives us the rarest of examples of capital allocation (JSE: CMH)

Not only are they doing huge buybacks, but it’s instead of the dividend

In South Africa, many corporates are obsessed with the idea of paying an annual dividend and ensuring that it increases each year. To be fair, there are lots of mature companies in the US that are no different. As a reward for having an artificially low payout ratio and a dividend that keeps going up, those US companies even form part of a special club: the Dividend Aristocrats.

In truth, the decision to pay a dividend should always be weighed up against other capital allocation decisions. This is dividend theory 101, with the “bird in the hand” argument suggesting that the market pays a premium valuation for companies that show commitment to the dividend.

At CMH, we are going to find out if that theory holds in South Africa. Having just released results for the six months to August 2025 that reflect revenue growth of 16.3%, operating profit growth of 14% and HEPS growth of 22.7%, you would expect to see a juicy dividend. Instead, there is no dividend whatsoever! The company has decided to rather invest that cash into share buybacks, with a plan to repurchase up to 15% of the shares currently in issue. They won’t be able to execute a buyback of this size on-market and without shareholder approval, so a circular will no doubt follow in due course.

This approach to buybacks feels sensible, as these charts demonstrate that profitability hasn’t been nearly as smooth as the revenue journey thanks to all the distortions of the pandemic margins and then the significant change to the local market from the influx of Chinese cars:

Due to the cash-hungry nature of the operations from a working capital perspective, the cash generation story is even more volatile. For example, in the latest period, cash generated from operations fell by 14%.

When you’re dealing with this kind of volatility, buybacks give you flexibility that dividends simply don’t.

If we dig into the segments, then we find the usual situation that is such an amazing example of structural differences in margins. The car hire business generates profit before tax of R77 million from external revenue of R389 million, a profit before tax margin of almost 20%. The motor retail business has revenue of R7.1 billion, yet it only manages profit before tax of R104 million – a margin of just 1.5%. Talk about picking up pennies in front of a steamroller!

There is another element to the economics of the motor retail business that we need to consider. Selling cars feeds the financial services segment at CMH, which made profit before tax of R27.6 million from revenue of R74.9 million. That’s a margin of nearly 37%, which makes this the most profitable segment of the group!

CMH has done a commendable job of adapting here, with the management commentary noting that Chinese and Indian cars are nearly 50% of group new car sales. The traditional names at CMH (Nissan / Ford / Volvo) are really struggling. Hybrids are just 3% of the market, way below NAAMSA’s target of 20% this year and 40% by 2030. I have no idea how NAAMSA arrived at that target, but there is no chance of that happening here at the tip of Africa.

The car rental business also isn’t without its challenges, as they operate in a highly competitive environment. One of the ways they generate usage of the vehicles is the insurance replacement market. Now, we know from reading the results of short-term insurers that underwriting profits have been strong recently, which means that claims have been lower. Sure enough, CMH echoes this view in the commentary, noting a decrease in the level of insurance claims.


A juicy jump in AUM at Ninety One (JSE: N91 | JSE: NY1)

The rise in global asset prices has no doubt helped them here

There are literally only two ways in which an asset manager like Ninety One can increase its assets under management (AUM). The first is the “controllable” way, being the attraction of net inflows through marketing strategies and possibly a dedicated distribution network (depending on which asset manager we are looking at). The second is based on exogenous factors to a large extent, with an increase in asset prices over time leading to growth in the funds.

Sure, the company’s investment philosophy (which is controllable) will also have an impact on fund growth, but it doesn’t make as big a difference as the broader macroeconomic environment, especially not once you reach the scale of the likes of Ninety One.

There are a lot of concerns out there around global asset prices, but for now at least Ninety One is riding that wave. AUM as at 30 September 2025 came in at £152.1 billion, well up from £139.7 billion as at June 2025 and 19.4% higher than the AUM a year ago (September 2024).

The announcement doesn’t indicate the extent to which this is driven by asset prices vs. flows.


A nasty downturn at Santova (JSE: SNV)

Much of the strong recent share price performance has now reversed

In May this year, the Santova share price went mad in response to the news of an acquisition and subsequent buying of shares by directors and execs. My dad joke of the day is that the share price has now been Santova the edge:

As you can see, the drop came suddenly on the day of release of a trading statement for the six months to August. The company was impacted by lower volumes and freight rates in Africa, Asia-Pacific and North America. The resilient performance in the UK and Europe wasn’t good enough to offset the impact, which is why HEPS is down by between 20.1% and 25.1%.

The global trade environment is volatile to say the least.


Tharisa had a strong finish to the financial year (JSE: THA)

Q4 production numbers were excellent

Mining companies can’t do anything about commodity prices in the market, but they can make sure that their production is strong when those prices are lucrative. Tharisa has played their part in the latest quarter, with PGM production for Q4 up 19.7% vs. Q3. Chrome production increased by 2.9% vs. Q3.

Before you get too excited, I must note that PGM production for the full year was down 4.7% and chrome was down 8.5%. The acceleration in the fourth quarter wasn’t enough to offset the drop in production earlier in the year.

In terms of pricing, the USD price of PGMs increased by 18.6% for the year and 24.1% in Q4 vs. Q3. This jump in price is why the PGM sector has been flying. Chrome prices didn’t behave themselves though, down 11% for the full year and nearly 6% quarter-on-quarter.

The group’s net cash position improved from $43.1 million as at June 2025 to $68.6 million as at September 2025.

Production guidance for FY26 is between 145koz and 165koz for PGMs (vs. 138.3koz in FY25) and 1.50Mt to 1.65Mt for chrome (vs. 1.56Mt in FY25).


Nibbles:

  • Director dealings:
    • At Growthpoint (JSE: GRT), CEO Norbert Sasse retained shares worth R10.9 million as the non-taxable portion of a share award (meaty enough to deserve a mention – especially at this point in the property cycle). The company secretary of the company sold shares though, to the value of R857k.
    • The Chief People Officer of Quilter (JSE: QLT) sold shares worth R4.1 million.
    • Here’s some novel wording for you: Super Group (JSE: SPG) announced that the company secretary and a director of a major subsidiary sold shares “in part to settle tax obligations” – in other words, the sale was in excess of the amount needed for tax. I just haven’t seen a company word it that way before. The total value of the trades is R1.77 million.
  • AYO Technology (JSE: AYO) released the final timetable for the offer by Sekunjalo Investment Holdings and the delisting of the company. The listing will be suspended from 22nd October and terminated from 28th October.
  • PBT Group (JSE: PBG) has obtained shareholder approval to change the name to PBT Holdings.

Ghost Stories #75: A structured approach to global equity exposure

We know that global equities have outperformed global bonds and money market investments over the long term, but this comes with the risk of higher volatility. The current investment climate has also called into question the traditional 60/40 approach to a balanced portfolio, with problematic correlation for investors.

With a track record in structured products spanning 23 years, Investec has seen practically every type of market cycle play out. As a response to relative global equity valuations across multiple regions, Investec (in its capacity as investment advisor and promoter) brings you Advanced Investment Holdings.

This is a Guernsey-based structure that holds a portfolio of the S&P 500, Euro Stoxx 50, Nikkei 225 and FTSE 100 indices. Over a term of five years and one month, the investment offers full downside protection (100% capital preservation at maturity in USD) and will multiply the upside by 125% (to a maximum return of 50%).

Japie Lubbe brings his extensive experience to this discussion, explaining exactly why Investec has taken this approach to structured equity exposure in the current environment. He also explains the nuts and bolts of the structured product and exactly how the returns and risks work. 

Applications close on 28 November 2025. As always, it is recommended that you discuss any such investment with your financial advisor.

You can find all the information you need on the Investec website at this link.

Disclaimer

Listen to the podcast here:

Transcript:

The Finance Ghost: Welcome to this episode of the Ghost Stories podcast. It’s going to be a really interesting look at a new structured product that is coming your way from the team at Investec. And we’ve got Japie Lubbe on this one which is always exciting because Japie, you have been doing this for a quarter of a century as you pointed out to me before we jumped on to start recording. So that is an amazing innings – well done! You’ve basically been at Investec since the beginning of Structured Products there, right? You essentially launched this business with them.

Japie Lubbe: Yes. At that stage, you may remember we’d had the big ‘99 crash and 2002 was also a bad time for equities. So when we launched the product range we were initially focusing a lot on downside protection. Subsequently over the years we’ve had markets improving a lot and after the GFC we had like 13 years – what I refer to as Goldilocks years: porridge is always half warm. In that phase we introduced the autocalls and the digital notes and some of the others that you’ve had us on air, where in that type of product you do take some downside risk if markets move down by a certain percentage. And that’s served us well because it’s been a very long bull market.

This one we’re going to be talking about is one back to the product range where you have full protection just because at the moment our view is markets are quite high.

The Finance Ghost: I just want to touch on one or two of the points from the track record because it’s actually in the presentation that Investec has made available for this particular product. So roughly 126 public products over that period of which none have incurred a loss for investors. Absolutely none. So that is a fantastic track record – well done!

Four of them have returned capital to investors. So if we’re going to get technical, obviously their investors would’ve been on the wrong side of inflation, they kind of just got their money back. But that’s still a really decent outcome versus what would have happened had they just taken the naked exposure. And 85 with a positive return – so that’s 85 out of 89 matured structures with a positive return. And the remaining products, roughly 37 of them still live in the market, so obviously we’ll wait and see what happens to them at maturity.

So just well done Japie, I guess is the overarching point here. What’s interesting when you look at those stats is positive returns are great – I mean it’s nice to be up, definitely rather be up than down – but what about outperformance of the underlying indices? Because of course that’s the real goal, that’s the really, really big thing to aim for is not just that the returns were positive, you can technically achieve that by just putting your money in an Investec bank account actually and earn some interest – you want to outperform.

What’s been the journey with that? You’ve been there from the beginning. There’s no one better to talk to that than you.

Japie Lubbe: Yes. So we have three listing platforms. We have the Johannesburg Stock Exchange, we have the Dublin Stock Exchange for hard currency notes. Those two products are on Investec’s balance sheet, so the investors are taking Investec risk, Investec issues them with a note. And then we have the Guernsey companies listed in Bermuda. And these companies are totally independent companies. Investec doesn’t own any assets in them. They’re totally independent. That will be the one that we’ll discuss today.

So across these three platforms, of all 89 products that have matured and they’re shared amongst the three platforms, on the JSE our returns have been – average across all the matured products – 11.6% per annum. And the benchmarks that were the underlying assets of the indices that we’re tracking was 6.4%. On the Dublin market, this is now non-rand, so mostly US dollars – this has been a shorter-dated period, so it has had much more of these good times in markets – our returns were 9.6% and the underlying benchmark is 8.4%. These are the price-only indices.

And in the Guernsey companies we’ve had a very long period of time – we’ve had 23 years, and once again our returns have been in excess of the underlying indices and the extent of it has been that we’ve had – just for the listeners, maybe to start with something, the Guernsey companies is an investment for a five-year term and at the end of five years that share so to speak matures and they can stay and keep the shares or they can sell the shares. And they can also sell the shares intermittently, which will come to you a bit later in the liquidity. But importantly, these shares – over the term we had 23 of these companies – so it’s a Guernsey company, the client buys a share in the company, the shares last five years and the share has 100% capital protection and it has upside linked to markets, which we’ll give an example of shortly. And of those, we had 22 of 23 that matured where the clients made a profit. That’s 96%. They made a profit compared to the underlying indices.

Now we had a look at Morningstar, which has information about the best fund managers and all the fund managers in the world. And across all the fund managers, there have been just under a thousand that were trying to beat the MSCI World over the last five years and 30% could outperform the underlying indices after fees, costs and expenses. And over a 10-year, 34% could beat the price-only index. Our experience with the way we do it has been that we’ve beaten it 96%.

Secondly, when you look at total return, because as an investor you may want to say: how does my performance compare to the total return of the market? Across the 23 companies that we’ve had that have matured, we’ve beaten the underlying performance by 2.58% per annum for a five-year term across 23 companies. Now, the fund management industry, which is not John, Peter or Paul or A, B or C, it’s just the industry – there were only 7.5% of fund managers over the last 10 years that could beat the total return. And because we beat the price only by 2.58% per annum – the average dividend yield on all these underlying companies for all that period was under 2.58% – so effectively, after fees, costs and expenses, net investment to the customer, they beat the total return by doing it the way that we’ve done it here.

Now it’s very important to highlight that this return was achieved with taking the credit risk of the banks that we used. Because in our structure you don’t own the shares underneath directly, you don’t own the bonds directly, you own a share in a company and that company makes investments and for that you’re taking credit risk. But also interesting is that because we’ve done this for 23 years – it’s been a long time – and we know with investments you must always test something over different cycles. We’ve had early years like 2008-12 was a very big GFC crash, then we’ve had some very good years. So it’s good to have a product that you can test its performance over various cycles and over a long period of time.

We found that 30% of our outperformance came from not losing when other investors lost. So in the world of your portfolio management, over a long period of your money, it’s very important that you have a portion – and our offering is always only for 15% to 20% of the total, we don’t put all the client’s money in this – it’s very important to reduce the opportunity for losing. The loss is the important thing to avoid.

Now you mentioned earlier that we had these four where we returned capital – just to give the listeners some sight of it, one of them, the one that had the worst performance in the physical world, the equities that were our underlying indices were down 44% over the five-and-a-half -ear term. That was a five-and-a-half-year one. And our investors got the hundred back. Now if you don’t take a 44% loss, what you do is you take your portfolio actual current value and you can add on top of that the loss you did not incur. So if you lose 44% and I lose nothing and we both go into the market tomorrow morning at spot, because that’s what will happen at the end of five years, if I have a hundred in my hand and you’ve got a statement telling you you’re worth R56, maybe R58 with positive alpha or R52 with negative alpha, but roughly R56, okay, you’ll have a hard time catching up. So this is very important, is that this structure is there to give clients over the long term, and we’ve seen that on aggregate stellar return, and they must allocate an appropriate portion for the risk they’re prepared to take on the supplying banks.

The Finance Ghost: Japie, that’s fantastic. That really does give so much context to this whole story. And I love that you’ve brought up the fees there as well because I think that’s an important part of comparing these Investec products to anything else in the market.

And interestingly enough, even if you look at the index, you actually really need to be looking at an ETF because you can’t just go buy the index, you have to buy it through an ETF which has some fees, low fees admittedly, but something, it’s not zero. Even if it’s 20 basis points, it’s still something and that adds up over time. So that’s the fairest comparison, right, is to actually say, well what is the ETF you could have bought on that index, compare it to some of the structured products and then see where you come out.

And obviously there are pros and cons to everything, as always. An ETF has immediate liquidity, it’s not a multi-year structure. Your minimum, you can go and put in 10 bucks if you want through your friendly local stockbroker.

It’s not that structured products are better than ETFs in every single application at all, but the point is that for the right clients, you are able to actually point to this amazing track record. So congratulations. I think it is, it is very, very cool.

Japie Lubbe: If I could add one further point for consideration in that discussion. If you were to buy an ETF and let’s say an MSCI World ETF for five years and you didn’t want to take the risk that the market goes down over these five years that you were holding it, you can buy a put option. Now, a put option’s like you’re buying car insurance, household insurance, medical aid, you’ll protect an asset, but you’ve got to pay a premium and you’ve got to pay the premium up front.

And we’ve priced it – at institutional level, a premium would cost you 12% of your money. So if you had $100, you’d have to pay away $12 to protect the $100. But you would get the dividends, but you’d only get 88% because you had to pay the $12 up front. So when you look at returns like we’ve had, it’s very important to appreciate that over the 23 years of five-year protection as a separate investment would have typically cost 10% to the investor. If you’re getting these returns and you didn’t take the risk because remember, they were without the risk, then that utility is worth 10% more. Okay, so what this actually proves is because we’ve had cycles where we’ve had down markets and up markets, it’s that inherent value that comes from not having lost, but without having to have paid insurance premiums for doing so.

The Finance Ghost: Yeah, there’s a lot of cleverness in the maths, there’s a lot of cleverness in how this thing actually works. And we’re going to get into the nuts and bolts of the latest product.

But I think before we do that, Japie, it’s such a good opportunity to tap into your extensive market experience. While you were busy launching this thing amidst the dot com bubble and the aftermath of that and everything else, I mean, I was finishing primary school, literally, so it’s always so fun for me to have you on the show because I always get to learn a lot from you as well, which is brilliant. And one of the things that’s been a discussion point in the market recently is that traditional 60/40 split of equities/bonds. Arguably maybe some outdated thinking about whether or not that actually works well as a tool for diversification and growth. It feels like the last few years has been positive correlation between bonds and equities as opposed to the negative correlation that actually makes that work from a diversification perspective. And this is something that you’ve raised in the presentation for the latest product, so this is not just a completely random point, this is something that you guys are thinking about when you put these products together.

I guess let’s just start with what you think is driving this reality where correlations have changed and what risk does that then create for investors if they actually follow the traditional approach and they just blindly do the sort of 60/40. Why is this relevant in your world and why do you think investors need to think about this?

Japie Lubbe: If we have a look in our presentation, we show the last 26 years of total return on equities – MSCI World – versus total return of bonds. And it’s interesting to note that equities obviously have massive gyrations or volatility in five-year type returns. You can have a fantastic time or you can have a negative time. Importantly, the aggregate total return – and this is no fees applied, just the market – was 6.7% per annum for equities and was 3% for bonds. And it follows the empirical knowledge that we have that equities tend to – because inflation was for that 26 years average 2.6% – so bonds had a, let’s say below average type of very long-term returns. Possibly because we had equity interest rates rising in the world in the last few years, but they still gave a real return, bonds.

Equities gave what is on average a 4.1% per annum real return, inclusive of dividends. So it follows that a lot of investors have said to reduce the volatility of the equity, I buy this 40/60 split and although I’m getting a lower return on the bond component, it is mitigating the risk of the equity component. Now we come along and we have a look at this and we say but if you look at the cycles, what you’ve had of late is that you had interest rates go in the world from let’s say the 1.5% / 2% to 4% / 5%.

Interest rates went up across the world after Covid and with the amount of money supply that the governments are putting in to the system. Because remember what they’re doing is printing money and they’re creating more supply of money. So this has the consequence that interest rates went up for multiple reasons. But at such a time then bonds are inversely priced. The bond component of a 60/40 gets hurt when interest rates go up. And when the interest rates go up and the bond yields rise, firstly the bonds’ valuations come down. But secondly the bonds become now – for the new investor – more attractive than equities. So you get a switch, institutional switch from equities to bonds because now they’re anticipating a real return and it’s less risk. So what happens is that the correlation actually increases – both the bonds are going down in price – as a consequence of that, they have a higher yield – and now the equities go down in price because the people are switching out of the equities into the bonds.

And conversely, if the interest rates come down, like you’ve seen in the most recent past, there’s interest rates coming down, now look how hard the equities start running. So the correlation is the rates come down, the bonds are more valuable, they have a higher price and equities go up. Because the alternative to go into bonds is viewed as less, so equities attract more cash.

Okay, so put the two together. We’ve just recently been in a conference in Switzerland given by international players where they anticipate going forward, the anticipated return if you just take historic norms, is about 6.5% per annum for a 60/40 split.

Now what we’re going to show you – what we’re doing here is we create something which has got a maximum return of 8.3%, but with zero downside risk as opposed to the 60/40 split. Because we believe that if you can have equity as your asset class, but have protection on that equity, then over time that’s a good blender. It’s not that you have one or the other, it’s just an addition to the portfolio and the amount that you put in would depend on your client’s personal circumstances.

The Finance Ghost: Would it be safe to say that with the latest product you really are competing with, at least to some extent, balanced funds and that way of thinking? That’s very much where you’re pitching this, right?

Japie Lubbe: Yeah, definitely. And also obviously hedge funds, because hedge funds by definition try and give you a return where your perception is that your capital is more protected because they can take short positions, long positions.

So in a portfolio, an investor would want some racy potentials, let’s say direct equities, hedge funds possibly, and then they’d like some more sort of “sleep well, eat well” stuff where that’s your core portfolio and this is where this competes with the ETF, with the fund managers that are trying to beat the ETF and with the balanced funds.

The Finance Ghost: Super interesting. We know now we’re talking equities, that’s effectively where this latest product is focusing. There’s a basket of indices in it and we’ll talk about that just now. And certainly something that I do when I do my stock picking specifically, which is obviously something I love, I always look at the current valuation multiple versus historical averages as one of the points to look at. If a stock is trading at a P/E of 20x and for the last 15 years it’s been on a P/E of 10x, you’ve got to ask yourself some very, very big questions about why on earth the P/E has doubled and is that remotely realistic? And I know it sounds crazy, but if you look in places like the US market, it really is like that. P/E multiples are sometimes double or more their 10 year averages, less so in South Africa certainly. But in terms of index level stuff and capital allocation to various indices, you would look at those average multiples as well, right? You’re just doing it at index level to say, well, here’s an equity market that relative to historical averages is either cheap or expensive. Is this one of the building blocks in your approach?

Japie Lubbe: Yeah, absolutely. In our presentation we show that the MSCI World All Country Index is currently trading at a price/earnings ratio of 22.1x and the long-term average was 19.5x. On a relative valuation at world index level, it shows that markets are expensive. They’re not massively expensive, that is, they’re not like two standard deviations expensive, but they are definitely expensive. And then in the context of that, the US is really expensive compared to the others.

When we do our products, we’re obviously cognisant that if the market’s so expensive, what you really want to as an investor is be certain that you try and protect some of the value you’ve made by having this capital protection. But importantly, we don’t think that it’s suitable for clients to say, I’m just going to take all the money out the market now, put it in cash. Because the long-term average and the long-term stats show that cash and bonds far underperform equities. And in the context of what’s happening in the world with so much ballooning of debt on national balance sheets, the debt is increasing massively and the counter-side of the balance sheet is the assets. The assets are creating inflated asset values in bitcoin, gold, property a bit less because interest rates are too high, equities.

As an investor it is really penal to say I think the markets are very high, so I’m going to take all the money and put it in bonds or cash. You can’t do that. What you’ve got to do is stay with the equities, but on your allocation, maybe go more for defensive equities, either on a style, or on small cap versus big cap, etc. etc. But in the structured product space, allocate to the structured product which gives you the capital protection in case it’s a bad time, but stays with equities. So that’s really how we’re seeing it.

The Finance Ghost: There’s an important point you’ve made there which is stay with the equities because obviously we all wish we could time the market perfectly, but there is so much uncertainty out there. There are so many things that drive the market, so many geopolitical things, so many things that are just completely outside of even the ambit of what the management team of that company can control or even the country where that index is found could possibly be expected to control.

Volatility is just a feature, not a bug of the market, right? I mean, that’s part of why we can all earn a return from it and why you get paid to be there is because of the volatility. So, staying with equities is important. And yes, you can certainly allocate more in relative terms when something is a bit cheaper. But the problem is if you try and get too cute, which is your point, then you miss the best days in the market. You’ve got to be in it to win it. If you’re sitting on the sidelines and that best day happens without you and then you climb back in, long-term there’s some interesting maths that says that this is not good, right? That approach will hurt you.

Japie Lubbe: Absolutely. In our presentation, we show that if you take the last 20 years of the MSCI World and if you were fully invested for every single day of the 20 years, your total return was 8.2% per annum for the last 20. But if you missed the best 10 days, to your point, then it goes down to 4.9%. And if you miss the best 20 days it goes to 2.7% and if you miss the best 30 days, it goes to 1%. So two points that come out of it, and that is that if you look at from 2005 to now, if you’d been putting a hundred dollars in the market every year and you had the best timing possible, you would have gone to $7,200. If you picked the worst days possible to put your $100 in the market, you would have gone to $5,400. But if you stayed in cash, you’d have been at $2,500. So it is extremely penal to try and time the market. That’s why you know the old saying: it’s time in the market that makes the money.

So two things that come out of this history. Firstly, the fact that if you’d been in every day for the last 20 years with dividends and no fees i.e. like an ETF, MSCI World will have given you 8.2% per annum. This is what we target for our product that we’re doing now. We’re saying if at these levels you can for the next five years get that, but not have to put your capital at risk, that would be a great outcome.

The Finance Ghost: Yeah, it’s very interesting. And this is all of the thinking that obviously goes into the products that you guys put together at Investec. And there’s a few of them every year, well, more than a few. They come through kind of thick and fast and they’re always a bit different, which obviously makes these podcasts really useful and interesting for those particularly trying to just understand what’s going on.

And the latest example is called Advanced Investment holdings, and as I mentioned, this one is focused on various equity indices. So that’s the building blocks of this thing, essentially. I think let’s start there, Japie, if you could just walk us through what is the basket of indices that you’ve decided to allocate to here. And I guess why – what made you choose them? What made you choose those weightings as well?

Japie Lubbe: Sure. So firstly, this is an existing company, it’s called Advanced, and it’s going into its umpteenth phase. The shares, as we said, are issued for five years. The existing investors have now got the chance to roll those shares, lock in all their profits and have a new capital protection level. And they’ve made roughly 60%, last five years, in dollars. Secondly, new people can come in and for new people that come in, the minimum is $12,000. That’s the minimum threshold. It’s a five-year-and-one-month term because you’ve got Christmas coming up shortly and you’ve got 100% capital protection if you stay the full five years.

The upside is linked to a portfolio of indices where the weightings are 35% S&P, 35% Euro Stoxx, 20% Nikkei and 10% FTSE. If you back test that, that’s 90% correlated to the MSCI World Developed Markets. Now we’ve specifically, to your point, underweighted the S&P because our internal valuation is that that one’s very expensive and frothy. So we’d like to allocate less to it because we think the opportunities are better in the other markets.

But we can’t reduce it too much because the US is too important a place in the world. By reducing it to this threshold, we still get to a 90% correlation to the World Index. Now, performance wise, these investors will get 1.25 of what the index does until the index hits 40 on those weightings. And that’s all in US dollars.

Now, just because markets are volatile and the like, what we have done at Investec, we’ve hedged out the risk to interest rates for a portion of this, but we don’t know how much we’ll sell. We normally sell very large trades. So we reserve the right to make the 1.25 as low as 1.15.

But what this means is that if the market did 40 just on the current pricing at 1.25, the investor would make 50. So it’s like saying to you, you buy a share and if the stock exchange goes down 40, you get your $100 back and you can buy the market the next morning, it’s priced at 60, with 100 in your hand, if it crashed.

If it went up, then to avoid you feeling that I could have picked the shares better myself or gotten someone to manage my money, you’re getting 1.25x what the index does. Bearing in mind that we said only 34% of the fund managers after fees, costs and expenses could give you one for one. So now you’re getting 1.25 for one and you’re getting this until the index is 40.

Now why 40? Because if we said looking in the history, the average 5-year total return on the market was 6.7 and if you compound that number, it comes to 38/40. So we’re saying if the market’s already high and you take what they did, bearing in mind that they had all-time highs, okay, the history and if you can get that as an average return, it’ll take you to 40. You compound that now with 1.25. You’re getting 50, getting 10% more, which is in fact more than the anticipated dividend yield because the dividend yield is about 2 per annum.

So it’s like you can now get the total return, okay, but you are going to lose out if the market does 55 or 60. But you just got to ask yourself, what’s the likelihood? And remembering now, this is part of your portfolio and so you’re not going to be very unhappy if you can get 50% in dollars over five years from these levels. That’s really the makeup of it.

How we do it, maybe just to go to the maths, is we get the money into the company. Let’s say that’s $100 / $200 million. We’re going to take roughly 75.9% of that to buy a credit-linked note from a bank. And we’ll go through the credit in a moment and that over the five years grows to 100. Now, this company that we have in Guernsey that we put the money into, we’re the investment advisors to the company, Investec, and that’s our only role. The bank doesn’t own shares in this company.

So the 75.9 grows through to 100, and we put 7 aside for fees, costs and expenses. That’s for the distributors, for us, and Grant Thornton as auditors, because this is a highly regulated company. It’s regulated in Guernsey, Bermuda and South Africa under the Companies Act and it’s been signed off. The 7 amortises to 6, 5, 4, 3, 2, 1, 0 over the time. Not all up-front, gradually.

And then lastly, we’ve got 17 left over. If you take the first two numbers from 100, there’s 17. And what we do with the 17, we’ve got a panel of major banks. They have to have a credit rating of S&P A or better to price to us. And we say to them, if we were to buy a call option, what would it cost? A call option gives you 100% based on 100 of whatever the index does. And so that would cost 17 as we speak, we said, and if we sell you a call option at a level of 140, they say, well, we’ll give you a rebate. And the rebate is 3.4. So it follows that if something costs 17 and you take 3.4 off that, it’s 13.6. But you still have 17 cash flow in your hand, so you can buy 1.25.

So that’s how simply the leverage works. It’s not like many hedge funds do where you borrow money from a bank. We’re not incurring leverage by borrowing money which has an interest charge associated and which could be favourable or not favourable. It’s just absolute cash premium.

The two things to observe here is the fact that the fees, the 7.1 are part of the original hundred, so we say they baked into the cake. Secondly, that this structure has no outperformance fees. It doesn’t enable Investec to charge the client because they made a lot of money, more than some threshold – all the returns accrued to the client. And because we’ve got this open architecture in our company, in other words this company can buy the debt from any one of five big banks, it can buy the options from any one of five or six big banks. And we’re the option structurers at Investec, we can get the best price from the best bank, so a shareholder goes in for $12,000, gets price calibration for a $200 million investment because they just own the same shares as anybody else in the market.

Whereas the small client if they try to go and engage a bank and buy their own product then they wouldn’t have the same buying power, they wouldn’t have the same ability to leverage volumes. And this is what we do for our clients.

So that’s really the mechanics of that, how it works. And after five years – let’s quickly fast-forward five years, the stock exchange can only be up or down. It’s like life, you’re either lucky or you’re unlucky. If you’re unlucky, it went down. If it went down 40, you say fine, let’s accept that. But now I’m getting 100 back and I can buy the market at 60 the next morning, saving the loss. Secondly, if it’s been positive, you can say, well, I’ve made good money. I’m still at an age where I need equity, I must always have equity and I roll the share. If you roll the share, whatever profits were made in that phase is now included in the new capital prediction that you have for the next phase.

In this manner, you can stagger like five-year intervals and just sit out one day when there is a crash, if there is a crash. 200-year equity history shows that problems come, but they come like a thief at night. You don’t know when they’re going to come. It’s very important – and this is why at Investec you’ve seen we have eight of these companies so that every six months, every nine months, there’s one rolling. So every six or nine months you’re locking in whatever you made for that period. If there is a correction, you only lose the amount that has been growth above where you last locked in.

And this you can’t do with equities or ETFs or unit trusts. You’ve got to take your chances. And if you want to make the money, you got to sell the investment. When you sell an investment, you’re liable for tax – only when you sell the investment.

The one thing I would just like to quickly cover as well as the credit. So who do we buy these bonds from? How does it actually work? We have a panel of five banks where we can potentially buy the note that protects that capital. And those are depicted in our documentation and include Citibank, Goldman Sachs, Morgan Stanley, Bank of America or BNP Paribas.

They issue us a note and then in that note they reference five of six banks that we agree with them. The reference is to the tier 2 debt, the debt that’s subordinate to the depositor. This debt ranks ahead of ordinary shares, preference shares, perpetual debt. Now, no bank that we know of since the GFC has actually defaulted on this type of debt. This debt is all investment grade ranked worldwide debt. But what we do to make the risk as low as possible is we allocate 20% to one of five names. And the five are Deutsche Bank, Commerzbank, SocGen, Barclays, Standard Chartered and Santander Bank. The actual debt is rated in the market by rating agencies and it’s all investment grade rated, much better than our SA government rated debt, because our sovereign isn’t at that rating.

So what happens if something happens with one of these reference entities, let’s say Santander, I’m just using an example? Then there’d be a recovery percentage on that debt and that would be a total of 20. So let’s say you recovered 50%, you’d lose 10. But the equity share upside is independent of the debt. As I say, over all those that we’ve done in history, none of those are defaulted. And, worst case, if as a shareholder you weren’t happy with Santander, intermittently you can sell your shares.

The Finance Ghost: Japie, so much experience coming through there, which I just love. I think, to maybe anchor people back to the underlying equity indices that you’re using here. The one thing I just want to highlight, underweight S&P certainly versus what a lot of people – not necessarily relative to the others in your basket – but certainly relative to what most people hold right now. And I think that’s an interesting point because it’s quite nice diversification for people who are sitting with very tech heavy, US heavy portfolios, which I would wager is most South Africans – when they go offshore the default setting is “I want the US” and that has worked really well in the past few years. That’s exactly where you wanted to be.

But the point is that a lot of those valuations have gotten to a stage now where if you back up the truck and you go and buy a ton of S&P 500, there’s no guarantees that you’re going to do well. You might even underperform some of the other options in the world. So that’s where a product like this becomes interesting.

The other thing that I think you made clear there, which I always appreciate when you talk through these structures, is it’s not actually a black box. Everything is there in the documentation that deals with the structure in terms of what you do with the money. No one has to guess how you get to the point where there’s downside protection, upside multiplier, etc. etc. It’s all there – fees included. So that’s quite different to – or not quite different, it’s entirely different to how international hedge funds, bluntly, any hedge fund works. You don’t get to see every single thing that’s in the hedge fund all the time and it’s going to change every day. Whereas here, what you’re saying is, look, here’s a return profile. This thing exists today, it’s going to exist for five years, whatever the case may be. Five years and one month this time – and this is what we’re going to do with your money. It’s set out for you. You don’t have to guess, you don’t have to worry, you don’t have to wonder if someone wakes up one morning and had a bad day or makes an emotional trade or all of the other things that come with active management.

Active management done well is amazing. But as you say, the stats tell us that there’s only a portion of active managers who can actually get it right and most of them don’t. So lots of interesting stuff coming through there. And I think maybe this is a good time to talk to just the liquidity because as you said, in life you can either get lucky or unlucky, it’s like the market goes up or down – unfortunately, that is true for life. And sometimes life happens and people do need to get their money before the end of the term. I mean the flip side of that is life goes beautifully and you invest in this thing and it compounds and you roll it. And I’m sure you’ve had clients who have done that from the beginning or hopefully from the beginning, I’d actually love to know that. And then the flip side of that is if something goes wrong, what is the liquidity availability if someone needs to get their money out? Death, divorce, take your pick.

Japie Lubbe: Yeah, sure. So, having done this for 23 years, we have had obviously a number of people who have faced those liquidity requirements. And there are three levels of liquidity. So the first level of liquidity is John wants to sell and Peter’s happy to buy. Willing buyer, willing seller, shares transferable, no costs. And normally this happens at advisor level. The advisor’s got two clients and the one’s wanting to sell and the other one’s prepared to buy. So that’s very simple. That happens maybe 5% of the time.

95% of the time, or 94% of the time, a client wants to sell and we haven’t got an immediate buyer. We have roughly 26,000 transactions on our books, so in other words, our business is now, let’s say R48 billion of assets. And so there’s a huge base of people to understand how this stuff works. We have a secondary market process. And what we as Investec do is we provide market making function whereby we buy – this is the second level of liquidity, which is mostly utilised, you want to sell the shares, it’s the prevailing price, that day’s price, less 1.25%. Much like if you sell your Sasol, your Anglos, you’ve got a back-end fee to get out.

So there is a process that follows – it’s normally about a week or 10 days to do it because we’ve got to notify the directors in Guernsey. It’s not like you’re picking on-screen, you sell your Sasol and tomorrow morning you got the money in the bank account. It’s not that liquid. It’s not as liquid as a traded stock, which you would expect to sell today and tomorrow you see the cash in your account. But we’ve not had any clients who’ve tried to sell over the 23 years and not been able to sell.

Now the third level of liquidity is we have a portfolio that we can utilise to buy this.

If we are full up on our capacity or we don’t like the share, then what we do is we unwind the underlying assets. Because remember, we’ve bought a bond, the bond’s got a value in the market, that’s how we pricing it daily. And options are provided by bank which we can provide liquidity requirements with that bank when we trade with them. We say if we want to sell these options back to you, you’ve given us a daily price. And we agree with them that they’re prepared to buy this back because this is very infrequent and small compared to the trade size. To put it into perspective, let’s say of these Guernsey companies, the ones that we’re talking about Today, we’ve got $1.8 billion in our book. We maybe have $1 million, $1.5 million available on stock. Because what happens with options is often a lot of value comes in at a latter stage of a five-year term. If you’ve heard of the J-effect of options or hockey stick effect. And so that’s when secondary buyers we see line up to buy and we’ve got specialist people have worked out how the secondary pricing works and are always on the lookout for the low hanging fruit.

So it is not clever to sell early, but you can sell early. And why it’s not clever is invariably certain of the setup costs have been incurred, certain of the annual fees that have to be deducted have been deducted. And most importantly, certain of the option profits will come at maturity when there are no bid-offer spreads on the debt or the equities. So we haven’t had anybody try and sell and not be able to get out.

The Finance Ghost: That’s again a really important part of the track record I think, because life does happen and it’s important that people understand they are signing up for something that has a minimum term here, but in the event of, you know, some kind of disaster, it’s not handcuffs, you can at least get out even if you have to take a little bit of a knock at the time.

Not really that different to anything else you might own, but maybe just slightly different.

I think maybe to start to bring this to a close Japie, those who are listening to this thinking “hmmm that’s a good idea, I’m interested” – how do they go about investing in this product? Do they need to always go through an advisor. Can they contact Investec directly? You mentioned the minimums earlier, but maybe worth just highlighting again just in terms of people getting their money into this thing.

Japie Lubbe: Yeah, so the shares are issued to three decimal points. You can invest $12,000 or more. It’s like you can invest $12,200 or any number bigger than $12,000 and it’s just the allocation of the shares. So these shares can be purchased with the R1 million allowance per annum or R10 million that you can clear through SARS. People can buy in a company, in a local trust using asset swap and Investec and other organizations have asset swap capacity whereby you give them rand, they convert it for you to dollars and then they make the dollar investment. It can be purchased from offshore. So if the investor has a trust offshore or a company offshore, these companies have an ISIN number so they can be bought on online platforms.

I think the best would be anybody who’s interested is just to revert to us. We’ll ask them a few simple questions. If they are clients of Investec Bank there’s a process that they can follow through our private bank and through our My Investments platform. If they’re external we can chat to them and make sure what’s the quickest, easiest way for them to access the shares. But we do have 320 companies, distributors, 320 different organisations. So invariably if they ask their financial advisor, there’s a very good chance the financial advisor is one of our distributors. We will check that with them and give them guidance.

Because it closes on the 28th of November – so practically we want to close on the 28th of November, there’s ample time to clear these matters in advance – but you do need to give a FICA and let’s hope that we get off the greylisting, that would be a big advantage, so you have to go through that. And you may need a distributor or you may not depending on your circumstances. If you want advice, we have got access to roughly 2,000 financial advisors that we can put on depending where you live to make sure that you put an appropriate portion in and you have liquidity and all the other good things you need. But you know we’ve got some savvy investors who want to just invest directly and our process caters for both.

So we’ve got a team of six people that can easily respond, they indicate that they’ve got any requirements and the information that we’ve discussed here, both our 23-year track record, so the history of the products, plus the actual frequently asked questions which you and I have taken snippets out of, is available if they want to get the material, have a read up, ask some more questions, we’re available to answer.

The Finance Ghost: Brilliant, Japie, I will include the link to that in the show notes and yeah, I think we’ve done a great job of really just running through not just the nuts and bolts of this thing, but also the thinking behind it that leads you to the way you build these products, the goal, where they fit into a portfolio, how to access them and what they do. So thank you – I think it’s been a really good run through of the latest product.

I don’t really need to wish you luck because you’ve been doing this for 25 years and you’ve done 126 of them and counting, so I think you’ll be okay on this one. But thank you as always for I guess for just bringing the story to the Ghost Mail audience.

And I would encourage listeners, obviously do your research, speak to your financial advisor, all of the usual T’s and C’s, disclaimers, caveats apply. The track record here is incredibly strong and so obviously this is something that I think you could certainly at least consider as part of your broader capital allocation strategy as you look to build wealth in this uncertain and slightly chaotic world that we live in.

So Japie, you’ve seen plenty of that chaos over the past 25 years, you’ve seen a lot of good stuff too. You bring all the experience to this chat and it shines through every time. Thank you for making time and as I say, good luck with getting this one across the line and enjoy what’s left of your 2025.

Japie Lubbe: Thank you and thanks to you and your listeners.

This podcast is for informational purposes only and does not constitute advice. You must speak to your independent financial advisor before investing in any product, and especially this one. Investec Corporate and Institutional Banking is a division of Investec Bank Ltd, an authorised financial services provider, a registered credit provider, an authorised over the counter derivatives provider and a member of the JSE. Ts and Cs apply to this product and you should refer to the Investec website for full details.

Ghost Bites (Aspen | ASP Isotopes | Boxer | Calgro M3 | Canal+ and MultiChoice)

Aspen released a positive update – something the share price desperately needed (JSE: APN)

The market cap has shrunk faster than the waistlines of GLP-1 users this year

Aspen’s share price closed 3.5% higher on Monday on a day when the ALSI was up 0.9%, so the market clearly appreciated the latest news from the company. In truth, Aspen shareholders will take whatever good news they can get at the moment, with the share price down 39% year-to-date.

In this case, the happy news for Aspen is that the South African Health Products Regulatory Authority (SAHPRA) has approved the use of once-weekly Mounjaro injections for chronic weight management. Of course, they make the usual disclaimers around using this in conjunction with a reduced-calorie diet and increased physical activity, but I think we all have enough anecdotal evidence from the internet or from friends using GLP-1 injections that the exercise tends to be an optional extra.

Mounjaro is Lilly’s answer to the Ozempic craze that Novo Nordisk brought to the world. Aspen launched Mounjaro in December 2024 for the treatment of Type 2 diabetes in South Africa. My understanding is that the latest approval allows it to be prescribed for obesity specifically, which means that Aspen is excited about being able to target a wider market.

I’ll see myself out.


ASP Isotopes closed a casual 34% higher after releasing a business update (JSE: ISO)

They even got noticed by influential international FinTwit accounts

ASP Isotopes has certainly captured the attention of the market. The share price closed 34% higher yesterday on the JSE. Before you quite correctly point out that there’s limited local liquidity in the stock, I must note that the Nasdaq-listed shares closed 31% higher. In other words, this wasn’t just some finger trouble on the day in an illiquid stock.

The reason for the jump? The company announced that they’ve locked in their largest ever supply agreement for enriched silicon-28. They’ve also made a strategic acquisition of a radiopharmacy in the US to work with their PET Labs business.

The deliveries for the enriched silicon-28 are expected during the first quarter of 2026. The words “quantum computing” feature in the announcement and this certainly got the market excited, with “semiconductor” as the sprinkles on top. There are no financial details given about the order, so the market simply latched onto the concept and hit the buy button.

As for the radiopharmacy acquisition, this is a small deal in Florida that they expect to be accretive to revenues, EBITDA and earnings per share in 2026. It looks like a roll-up strategy is underway here, with PET Labs in discussion with multiple independent radiopharmacies in different jurisdictions for acquisition opportunities. ASP Isotopes is a business run by investment bankers, so you can be sure that acquisitions will continue to be part of the story.

ASP Isotopes is hosting investors at its facilities in mid-November, so it’s likely that the market will pay the stock even more attention after that.

There’s not a single mention of financial effects anywhere in this announcement, yet the market cap jumped by a third. What a time to be alive.


Mid-teens growth at Boxer – but a big drop in HEPS (JSE: BOX)

The impact of the IPO is still affecting the comparability of earnings

Boxer released results for the 26 weeks to 31 August 2025. With turnover growth of 13.9% and trading profit growth of 15.1%, the self-styled “People’s Champion” is winning among lower income consumers.

They’ve enjoyed 5.3% like-for-like sales growth, which is well ahead of inflation. This means that Boxer is enjoying continued growth in volumes, with the informal-into-formal retail trend providing a rare example of a genuine tailwind in South Africa.

Interestingly, like-for-like sales growth in the comparable interim period was up at 7.7% (vs. the latest 5.3%), yet total growth was 12.0% in that period vs. 13.9% in this period. This is because sales growth from new stores has accelerated, which is an indication that they are opening stores in better locations. I’m not sure if the conversion of some Pick n Pay (JSE: PIK) stores is having a positive impact here, but I’m guessing that’s at least some of the reason for this growth. There were nine new Superstores that Boxer that opened in this interim period and they are running 36% above budget for turnover, which is obviously excellent.

Speaking of store growth, Boxer’s distribution centre network has sufficient capacity to support store growth plans for the next 4 to 5 years. This is the case after the completion of the KZN Tongaat DC that can service 120 stores. This is good news for near-term capex pressure and bad news for near-term margins, as the facility will initially be underutilised.

Excluding the costs of being a listed entity, trading expenses were up 12.6%. Thanks to the turnover growth of 13.9% and the consistent gross margin of 20.3%, this means that Boxer would’ve expanded trading profit were it not for the new expenses of being listed. If we include those listing expenses, trading expenses were up 14.3%. The biggest chunk of this was obviously once-off costs (R41 million) vs. ongoing costs (R16 million), so that will give Boxer a softer base when they look back on this period next year.

Unfortunately, the good news stops after the trading profit line. Thanks to a 79.1% increase in net finance charges (a combination of balance sheet restructuring and the silliness of IFRS 16 that puts lease expenses on this line), headline earnings was up just 5.3%. Once you include the 51.1% increase in the weighted average number of ordinary shares, you get to a drop of 30.3% in HEPS!

There’s really nothing that the Boxer management team could do about the IPO, as they were simply passengers on the corporate journey that controlling shareholder Pick n Pay needed to send them on. To make it worse, they didn’t even retain the R8.5 billion proceeds from the IPO, as this was sent up to the broken mothership to try and fix Pick n Pay’s business. The full year numbers for FY26 will once again be impacted by the change in the number of shares in issue, so there’s one more report coming with a skewed base for HEPS.

A maiden interim dividend of 45.3 cents has been declared, so the market will now have that as a useful basis for comparison going forwards.

Digging deeper into the results presentation, we find that Boxer opened 25 new stores to reach 547 stores. This is part of the jump in net finance charges, as there are an increasing number of leases over time with costs that are recognised in that line. But the much more interesting strategic news is that Boxer Rewards Club now has 2.3 million members, which means that Boxer can start to tap into that rich data and generate additional sources of revenue.

The first six weeks of trading after period-end are described by the team as “strong” – a word they are heavily overusing in their announcement – so there’s not much insight we can glean from that in terms of momentum. As with all retailers, there’s all to play for in the second half of the year.


Calgro M3 is being valued by the market on earnings, not NAV (JSE: CGR)

This means that near-term earnings pressure is hurting the share price

Calgro M3 has had a rough year in the share price. While the local index marches to the top right-hand corner of the page, Calgro is down 19% year-to-date.

Aside from generally poor sentiment in the market towards SA Inc. stocks, Calgro is struggling with a market that just refuses to value the company on a multiple above low single digits. The market also isn’t interested in the net asset value per share (up 6.4% to R15.82 per share in the latest results), with the share price languishing at R5.26 – less than a third of NAV!

But where the market does focus is on earnings, with HEPS for the six months to August 2025 down by a rather yucky 18% to 82.86 cents. There’s also no dividend at the moment, so the share price doesn’t have any kind of dividend yield to anchor it.

The group’s capital allocation strategy is on full display in the latest earnings. The Memorial Parks business collected R51.64 million in cash, an amount that is in excess of the group’s administrative expenses of R45 million. There are costs related to the memorial parks of course, but this source of cash helps tremendously to keep things ticking over during a period of deep investment in the developments. In this period, cash utilised in operations was R50.6 million vs. cash generated from operations of R57 million in the comparable period – a swing of over R107 million! Property development is no joke.

When Calgro M3 moves forward with a big project, like Bankenveld District City, they have to put down expensive infrastructure. The revenue from this investment is only recognised upon finalisation of public sector agreements. This puts some pressure on the financials that the company needs to carefully manage.

The real pressure in this period came from a decrease in revenue of 11.59% in the residential property development segment. Although gross margin only declined slightly, earnings don’t stand much of a chance when revenue dips like this. Interestingly, the group actually doubled the number of unit sales in this period, so the drop in revenue is mainly because of lower infrastructure revenue in the reporting period.

Calgro M3 isn’t the simplest business to understand, but thankfully the management team is always keen to engage with investors and they are regular attendees on Unlock the Stock. The next event is on 23 October and you can register for free here to attend the virtual presentation and pose questions to the management team.


Here’s some great news – Canal+ will inward list on the JSE after the MultiChoice deal (JSE: MCG)

This means that investors will be able to access the broader entertainment and media group

Canal+ had to vasbyt to get the deal across the line, but they’ve done it. Having jumped through various regulatory hoops, the deal for MultiChoice (JSE: MCG) became unconditional and achieved so many acceptances that they are now well above the all-important 90% threshold.

Why is that level so important? Once acceptances hit 90%, the squeeze-out provisions can be invoked. This allows an acquirer to avoid an awkward and frustrating situation where a small number of shares remain outstanding. A squeeze-out forces the remaining shareholders to sell their shares to the offeror at the same price that everyone else got, so Canal+ will end up holding 100% of MultiChoice.

The really good news is that Canal+ is following through on its plans to inward list on the JSE. This idea was floated around as part of the deal, but we now have a concrete commitment. I’m always excited to see listings on the JSE, with the Canal+ and MultiChoice combined group serving more than 40 million subscribers across nearly 70 countries. This is a scale player in the world of media and entertainment.

Of course, this also means that the financial turnaround of MultiChoice will be taking place in public, even if only in the form of segmental disclosure in the financials. I look forward to seeing what happens here.


Nibbles:

  • Director dealings:
    • The exec in charge of ADvTECH’s (JSE: ADH) recruitment business has sold R34 million worth of shares. The announcement notes that this is a Section 42 transaction, which is typically just a personal restructuring of how the shares are held. In such a case, there usually isn’t a change to the indirect ownership. The announcement unfortunately doesn’t specify the extent of the change to indirect ownership.
    • Three directors / senior execs at AVI (JSE: AVI) were awarded share options and sold the whole lot to the value of R13 million.
    • A director of Shoprite (JSE: SHP) sold shares worth R179k as part of a portfolio rebalancing. Companies love using this wording. In my books, a sale is a sale.
  • The offeror in the Barloworld (JSE: BAW) deal has achieved a beneficial interest of 58% in the company. The offer is open for acceptance until 7th November.
  • Mustek (JSE: MST) and Novus (JSE: NVS) released a joint announcement that the TRP investigation into the deal remains ongoing and hence a compliance certificate hasn’t been provided. This means that Novus cannot move ahead with settling the offer consideration to Mustek shareholders. The companies will release an updated deal timeline when the TRP investigation is completed.

The Finance Ghost Plugged in with Capitec: Ep 4 (A dose of inspiration with The Local Choice Pharmacy)

Introducing pharmacist and specialist retail entrepreneur Hugh Cunningham:

Hugh Cunningham is as passionate about customer service and product assortment as he is about medicine. As the co-owner of The Local Choice Pharmacy Harmelia, Hugh focuses on business management, while his wife and co-founder Yolandi ensures the dispensary runs smoothly. 

On episode 4 of The Finance Ghost Plugged in with Capitec, Hugh shares excellent insights on specialist retail and how pharmacies really work.

Episode 4 covers:

  • Why separation of duties and having a clear decision-maker is critical
  • The importance of doing proper financial analytics in any business
  • How pharmacies make money and the differences between independent and corporate pharmacy models
  • The benefits of being part of a franchise network
  • The future of the pharmacy industry and how independent pharmacies can stay competitive  

The Finance Ghost plugged in with Capitec is made possible by the support of Capitec Business. All the entrepreneurs featured on this podcast are clients of Capitec. Capitec is an authorised Financial Services Provider, FSP number 46669.

Listen to the podcast here:

Read the transcript:

Intro: From side hustles to success stories, this is The Finance Ghost plugged in with Capitec, where we explore what it really takes to build a business in South Africa. This podcast features specialist retail insights from Hugh Cunningham, co-owner of The Local Choice Harmelia pharmacy.

The Finance Ghost: Welcome to this episode of The Finance Ghost plugged in with Capitec. This is a wonderful podcast series in which I get to speak to some really interesting entrepreneurs. I get to dig into their backstory. I get to understand more about what they’ve built and why they are still build

The Finance Ghost: Welcome to this episode of the Finance Ghost plugged in with Capitec. I’ve been having a great time on this podcast season, talking to some really interesting entrepreneurs. This is episode four, which means there are three other episodes you should go and check out, covering everything from selling brownies at a market through to building a cosmetics business online and then doing property development and really touching every part of the property value chain. That’s episode three, so go and check it out. Huge variety. And we are adding to the variety on episode four here today because I am speaking to Hugh Cunningham. He is the co-owner of The Local Choice Pharmacy Harmelia.

So if you’ve ever wondered how the business of a pharmacy works, then you will find this to be a particularly interesting podcast. Hugh, thank you for coming onto the show and doing this with me. Powered of course, by Capitec and Capitec Business. I’m looking forward to chatting to you.

Hugh Cunningham: Thank you, Ghost. I welcome the opportunity to share some of my experience and insights at The Local Choice Pharmacy.

The Finance Ghost: Yeah, absolutely. So let’s get into it. And I think in line with the conversation I’ve had with others on this podcast series, it’s always good to just understand the backstory, a little bit of what brought you to this point, whether you were always interested in the space, I guess, from a pharmacy perspective. And then I think what is an interesting additional nuance is that The Local Choice Pharmacy Harmelia is actually a family business. It’s you and your wife, which of course brings all kinds of interesting dynamics to that as well.

So let’s, I think, start with just your background, how you got to this point, what got you into the industry, what is the backstory of you, essentially?

Hugh Cunningham: Sure. Thanks, Ghost. My background starts many years ago. In 1983, I qualified as a pharmacist. 1984, I spent a year in hospital pharmacy, then I went into production pharmacy. And while I was in production pharmacy, I opened my first pharmacy in Bedfordview, which I ran from 1985 to 1991. I then got married to my wife in 1991 and sold the pharmacy the same year. I then spent a fair amount of time in the pharmaceutical industry, in production, in regulatory affairs / medical information, then as a rep, then as a product manager, then as a GM.  Moved across to general management in the medical devices industry from where I moved into private equity, both with Anglo American Industrial Corporation and with ABSA Private Bank or ABSA Business Bank.

And then I moved into the recruitment industry, then back into the pharmaceutical industry as a sales director and then joined my wife in the pharmacy about three, three-and-a-half years ago. During all that time I also did an MBA degree in entrepreneurship with an Australian university and I did a postgraduate diploma in financial planning a year-and-a-half ago. Enjoying all of that but all the time – during that time I was also doing a lot of analysis for my wife, coming in the afternoons after work just to do the cash-ups and add value where I could to the business and I’m fortunate enough now to be with my wife and running the business together.

The Finance Ghost: Yeah, that’s fantastic and it’s a nice broad experience set, right, which I think is really valuable when you’re running a business because as many entrepreneurs have learned, either the easy way or the hard way, it almost doesn’t matter what you are selling. There are just key business principles that you need to get right. And I imagine that the prior experience that you’ve brought into this has probably made quite a difference.

Hugh Cunningham: Yeah, Ghost, I think it has made a big difference to the business. I think a lot of retail pharmacists probably don’t analyse their businesses well enough. So I think one of the skills that I’ve brought to the pharmacy is the analysis of sales.  I look at gross profit generally every single day. I make sure that systems are in place to manage the staff. I try and make the staff as happy as possible, but I think we really try and make sure that we’re doing the right things at the right time. And it’s quite nice because we try not to talk about business at home, but we do discuss business while we’re at work.

The Finance Ghost: So, Hugh, you’ve touched on a couple of really interesting points there. One is definitely around – and it’s a point I agree with, by the way, the fact that many especially smaller business owners do not really do the kind of analytics that you would expect to see in larger organizations, and it is to their detriment. I’ve actually worked with clients before, years ago, often they will leave their jobs to start some kind of small retail business and I would help them out on the side – just to help them understand margins, basic stuff like that, where if you haven’t actually studied something finance related, it’s not necessarily a guarantee that you’ll understand the shape of an income statement and the stuff you need to look at and the trends and the product level details and the category margins and all the stuff that makes retail incredibly interesting.

So that’s an important role that you play there with your wife, Yolandi. And I understand from you that she’s a pharmacist and you’ve been married, as I understood in the prep for this podcast, for a few decades now. So congratulations for that. That’s always a great achievement and you want to stay married, no doubt. So that means that you have to manage the business very carefully in terms of your personal life. What do you think has been the trick in actually making it work? I mean, you’ve kind of touched on already there, you know, not bringing work home, that kind of stuff. Would you say that that’s been the core trick to making it work as a husband and wife team, or is there something else that you think might be a valuable insight for anyone else listening to this who’s in a similar position?

Hugh Cunningham: Ghost, I think that the most important aspect of it is we share the pharmacy, but we have separate responsibilities within the pharmacy. We also sit on opposite sides of the pharmacy. I sit on one side and my wife sits in the dispensary and she takes more control of the dispensary side of things and I take care much more of the more business side of things. I do the staff management, the analytics, checking on stock receiving, etc. So yeah, separation of roles.

And because my wife has been in the pharmacy longer than I have, she’s been running the pharmacy since 2009 when we took it over and we became a The Local Choice in 2015. But she’s been running the pharmacy without me. I’ve been assisting until I joined the pharmacy full time and during that time she’s been the boss.  So I really try and allow her to make the decisions. If anyone asks me, I will say, well, she’s the boss ask her.  Being able to literally say, well, you know, it’s her pharmacy in the sense of she makes the decisions – I think that solves a lot of the problems up front. I think the problems would occur where we would try and say, well, it’s my pharmacy, it’s your pharmacy and then there’s a discrepancy. No one knows who’s really “the boss”.

The Finance Ghost: Yeah, I think there’s a good insight there and it’s true for actually all business partners. There are far too many who I think don’t have a proper separation of duties. So that’s the one point that you’ve raised there I think quite correctly. It doesn’t really help if two people go into a business with exactly the same skill set and they basically just fall over each other. That is generally unhelpful. So actually agreeing exactly who’s doing what is really valuable stuff and as you say, just also having someone who is going to make the final call. There’s almost nothing worse than a co-CEO environment where you’re at loggerheads and there’s the ability for a decision to not be made – someone has to have that kind of breaking vote.

So yeah, I think it’s a good dynamic and there’s a lot of reasons why it sounds like it’s worked. It was already operating before you joined. It wasn’t like the two of you sat down one night and said, well, let’s just roll the dice on this business and then we’ll see what happens. We’ll figure out what we each do and everything. That can be quite dangerous. So some really nice advice in there that I think is as applicable to any partners, business partners, etc. as romantic partners, husband and wife, married, take your pick, whatever you want to call it. I think there’s some great advice in there. So thank you.

I think let’s then tap into some of that business knowledge that you bring to it, because that of course is why we’re doing the podcast with you specifically, I think is because you bring that layer of the analytical business side and a lot of that sort of experience to this.  And obviously something that’s really interesting in the pharmacy game is big chains have become part of the landscape in a huge way in the last couple of decades and there are still a lot of independent pharmacies out there. People don’t necessarily realize how many independent pharmacies there are. I’ve done some analytics and work in that space before in a previous life, which was very interesting and I know the pharmacy licenses can play quite a role in that. It’s just interesting to see how these independents survive. The Local Choice is essentially part of the broader Dis-Chem Group. It’s a franchise that is serviced, to my understanding, at least, by Dis-Chem’s wholesaler, etc. and I’m keen to understand that properly from you.

But I guess let’s just start with understanding from you, your view I guess, on how independent pharmacies survive, why you went the route of the local choice. Just some of the business landscape stuff in this space?

Hugh Cunningham: Absolutely Ghost.  I think that for a number of years from 2009 till 2015, we ran essentially as an independent pharmacy with our own branding. We had our own colours, we had our own logo, and we ran and we had a lot of loyalty from our customers and were able to grow the business.  I think that when we got to 2015, we were one of the first The Local Choice pharmacies. I think we were in the second year of The Local Choice franchise starting up and we really gained a lot in terms of the broader franchise route, because The Local Choice pharmacies are a successful brand and people recognise The Local Choice.

In terms of how we work with the Dis-Chem Group, Christopher Williams, who is the owner of CJ Distribution in Delmas, eventually became the main distributor for Dis-Chem as well. So Dis-Chem Distribution is now CJ Distribution as well. So Christopher has managed to expand the wholesale side of it, so some of the smaller wholesalers have all become part of that whole Dis-Chem brand.  The difference between us and a Dis-Chem, is Dis-Chem is a franchise. Most of the businesses have Dis-Chem as a partner. So Dis-Chem has a larger say in the Dis-Chem franchises, whereas The Local Choice pharmacies are essentially privately owned.

How do we as a private pharmacy succeed in a market? I think there are a couple of things that really benefit us. One is we’re not in shopping centres. I think sick patients don’t really want to go to a shopping centre and sit in the shopping centre. They’re not feeling well, for starters, and they then have to go and get their medicine there. So easy access, parking just outside the pharmacy, I think that plays a role.

I think the major role, though, is service – when you come in, one of my absolute aims is to try and have as short a queue as possible in the pharmacy. People do not like queuing.  So if we can make it that there’s no more than one or two people in a queue at any time, that is what we aim for. And then the next is personal service and I must tell you that people come into our pharmacy and say, I want to deal with X or I want to deal with Y and if they want to do that, we’re more than happy to let them ask for that particular person to dispense their medication. I think the group pharmacies, the big corporates, you don’t get that opportunity. You may deal with a different person every single time.

So I think that makes a difference and then very personal service, trying to look after people – as I walk through the pharmacy on a daily basis, I greet – I don’t know – two, three, four people at any time. They all know my name, I know most of their names and certainly the staff that dispense them know them personally. And I think that makes a huge difference.

And then we also try and compete price-wise with Clicks and Dis-Chem. We don’t make huge profits, but my wife particularly will look at prices and she will say, hey, what’s Dis-Chem selling it for? What’s Clicks selling it for? Okay, we’ll sell it for slightly less. And it might not be R100 less, it might be R5 or R10 less. But we try to be price competitive.

So really, private pharmacy is a volume game. You need to get as many people in as you can and you need to provide a really, really, really first-class personal service.

The Finance Ghost: You touched on a lot of great points there. And it is actually something that is fascinating about retail is the location really is everything and as you’ve pointed out there, it’s those open-air malls where you can park right outside versus parking at a big shopping centre. It’s actually just a completely different experience and it lends itself to different kinds of shops. So thank you, that is interesting and you certainly confirmed something that I’ve always understood about retail.

I wanted to ask you one thing before I touch on some of the other points – are you required to procure everything from the Dis-Chem wholesaler or is it more of a SPAR model where you can actually technically buy from whoever you want, but you get preferred terms if you buy from Dis-Chem’s wholesaler?

Hugh Cunningham: Ghost, we can buy from any wholesaler that we would like to, but it’s to our advantage to keep as much as possible within CJ Distribution group.  So we can buy from CJ Delmas or we can buy from the major distribution group which is the one that does most of the distribution to Dis-Chem. But our preferred wholesaler is Delmas.

The Finance Ghost: Okay, fantastic. Thank you. That is very interesting and you’ve also touched on a number of the points I guess I was going to ask you anyway, which is around the service and when you look from the outside in, you kind of think “a pharmacy is a pharmacy” especially if you’re used to going to the big chains. A lot of that sort of faceless, nameless service that you’ve referenced there. I’ve personally not really ever had a sort of little village pharmacy, for want of a better description, where people know who I am and I know who they are. But I can see why that would be appealing from a community perspective.

If I think back to my childhood, we definitely had that. I think my mom used to go to the pharmacy just to honestly chat to them as much as anything else. But the world has changed a bit since then and it’s nice to see that businesses like yours still play a role and do that whole community thing and that you can actually make it work.

It’s obviously very important and like you say, it’s a volumes game. I mean, the one thing that I understand about pharmacy economics is that the dispensary is not where the money is made really. Obviously you can make money there and you have to make money there, but it’s difficult. The margins are not amazing on medication, pharmacists are highly paid people, so the economics of the dispensary itself are not so straightforward and that’s why people always talk about the front shop in the context of pharmacies, which is, as the name suggests, basically everything that isn’t behind the counter.

What has been your strategy around front shop and actually just making that work? I mean, I’ll give the example – Clicks is well-known for their small appliances. That’s because it’s a really nice way for them to juice up the margins of their stores as opposed to relying on dispensary. What has been your experience with that front shop versus dispensary balance?

Hugh Cunningham: Ghost, I think you’re exactly right and I think that corporate pharmacy is such that they’re really not worried about whether they make money in the dispensary or not, because they want the feet in there just so that they can make the margins on the front shop product.  In our case, about 78% of our business is from the dispensary and only about 22% is actually from the front shop. We don’t keep the full range of stuff that a Dis-Chem or a Clicks – the big corporate pharmacies – would keep. We try to keep the stuff that people buy on a regular basis. So our vitamins is a very big area. Then we keep a nice range of soaps and stuff like that. And my wife is excellent at choosing gifts, so we’re a very popular destination to buy gifts, particularly gifts for women, but gifts overall.

And then every now and then, we look at how we can remodel a business or what we can do to renew the business.  We’re now looking at another option that we could go for which would just expand the role. We’re looking at things like wheelchairs, walkers, that sort of thing, which are available in most of the corporate pharmacies but we’re now going to try and compete with them because we can give a personal service and we will also hire those out as opposed to selling them. So I think we try to renew the business on an ongoing basis.

The Finance Ghost: Yeah, that’s really interesting. I think you’ve touched on just how entrepreneurial it actually is to have a pharmacy, because at the end of the day, you’ve got the dispensary to drive footfall, which is the lifeblood of any retailer, and then you can kind of do almost anything you want from there in terms of the front shop. I mean, there’s obviously some categories that are not going to make any sense.

Actually, is there any kind of regulatory ruling or framework around what you absolutely cannot have in the front shop? Is there something that says, I don’t know, you can’t sell food or – well that doesn’t work actually, because Dis-Chem does that all the time, so it can’t be that.

Hugh Cunningham: Ghost, we’re not allowed to sell fireworks, we’re not allowed to sell firearms, we’re not allowed to sell ammunition, we’re not allowed to sell, sho there’s quite a long list of stuff that we’re not allowed to sell. Just trying to think of the others offhand, because we don’t sell them! Cigarettes, any nicotine products, we can give you stuff to try and stop smoking. No vaping equipment, no vapes, nothing like that.

So, yeah, there are very strict regulations about what we cannot keep. We’ve been in business here since 2009 and really we’ve stayed away from all those things. It’s just not worth going down that route at all.

The Finance Ghost: It sounds like a common sense kind of list for a pharmacy. You sometimes wonder about how the regulator sits around and comes up with this stuff, but yeah, that all sounds pretty sensible. And it means that you do then have a lot of flexibility for what you do with the front shop. Like you said, the gifts that Yolandi chooses to stock there and again, it just comes down to understanding the customer, right? Like any business, if you understand your customer, you can do well and if you don’t understand your customer, then you are at risk.

And I think there is risk of disruption to this space and that is something I wanted to ask you about, so I may as well do it now, which is a lot of what I read, especially overseas – I look at the likes of Amazon and what they’re doing. But there is some of it starting to happen here as well, is the concept of ordering your meds online and getting it delivered, basically just completely disintermediating going to a physical pharmacy. Obviously for you, that’s a core business risk, I guess? Is that something that you think about or do you think that actually medication is the kind of thing where people are still going to primarily want it in-store?

Hugh Cunningham: Ghost, I think that’s something that always occupies my mind. I’m thinking a few steps ahead of that even. But let’s look at it in terms of ordering online.  We have our website, we have a WhatsApp telephone dedicated to the dispensary, we have online ordering through email. So we’ve tried to address those options and we have two motorbikes going out and we have one little Suzuki which is fully branded so that anyone in the Edenvale area will see our little Suzuki driving around. Looks very much like the Checkers ones, except that it’s our colours and branding. So we try to advertise in that way. We also have an online advertisement that goes out to all the schools on a regular basis, and we get a lot of exposure that way.

But thinking further down the line, robotic dispensaries are becoming, I wouldn’t say common, but they’re becoming something that is happening. We can receive scripts directly from the doctor if a patient says, I’d like you to send it to XYZ pharmacy, we can dispense it from that point of view. So we’re trying to keep abreast of that.

In terms of the future and this is a concern of mine, is literally a doctor could write a prescription or type of prescription, send it to a robotic machine. The robotic machine could dispense the medication and there could be literally one pharmacist running five, six, seven robotic machines so that if a person needed to talk to the pharmacist, they could press a button and talk to the pharmacist. I don’t think that’s going to come in the next 5, 10 years, but in the next 20, 25 years, AI is going to take a very big chunk of every business, of every profession. And that’s my concern about retail pharmacy.

At the moment, I think people still like the personal relationship that they have with retail pharmacy, privately owned particularly, so I think we score there and we try and really make sure that we do those deliveries.

We also do a lot of blister packaging for retirement villages so that people get compliance with taking their medication on a daily basis. And that is doing very well for us in terms of the retirement villages in our area.

The Finance Ghost:  Again, a lot of really good general business points coming through – stuff like route to market, understanding the customer verticals that you can jump into, things like the schools, the retirement villages, etc. it’s all very clever – and there’s a lot of business experience coming through in your comments about, I think the robotics.

So typically, what people do is they overestimate the rate of change and they underestimate the extent of change. They think stuff will happen quickly and they don’t think about just how much it can change over the long-term. As you’ve described it there, I think is exactly right, which is the other way around, which is to say, well, it might not happen very soon, but long-term all bets are off – we don’t know. And I think that’s a very mature approach to disruption. I think that is typically what ends up happening and it will certainly be interesting to see what happens in this space.

I guess so much of it comes down to just maybe phase of life, what people need the meds for. I’m in my mid-30s  and I have to get medication every month that essentially keeps me alive, which is not great, but that’s what happens when you work too hard and you get a bit of burnout and you end up with something wrong with you that’s not so fantastic. But again, it’s – I know what it is, it happens every month. I get it, it’s done, whatever. There’s not really an advisory piece to it. Whereas I guess for people later in life, do you find that the customers who value the personal service, are they generally older and they’re looking for more advice around the meds they’re taking? It’s not really that they’re coming to buy basic flu medication and then they’re desperate for personal service? Or do you find that it’s not as cut-and-dry as that based on demographics?

Hugh Cunningham: Ghost, I don’t think it’s completely cut-and-dried. I think people really enjoy the personal service and I think what makes you stand out as a privately owned pharmacy, is making sure that people get good advice on their medication, when to take it, what could it interact with, how should I be taking it? We do have a fair proportion of our customers as slightly older people, but I think that that’s a factor that aged people generally are more sick than young people.  So, people in their 30s generally don’t have very strong medical aids. And elder people, they’re on the better options generally, unless they can’t afford them.

The Finance Ghost: Yeah, absolutely. That actually brings me to something I wanted to ask you, which is around medical aids and working capital and the strain this potentially puts on pharmacies. Because I’ve always wondered what happens in the background. Someone gets their meds, it goes through medical aid – I have a sneaky suspicion that the medical aids don’t do an EFT that afternoon into your bank account. So what does that look like in the back-end in terms of working capital strain on a business like yours? It’s obviously something all retailers have to think about, but in your case I suspect you end up with a situation where your customers effectively owe you, they just don’t realise they do because you’re waiting for their medical aid to settle!

Hugh Cunningham: That’s a very interesting question, Ghost. I think that at least there is a rule from the Council of Medical Schemes, that medical schemes have to pay us within 30 days.  They don’t always do it but most of the time we get our money back within 30 days.

Unfortunately, the entire medical industry seems to be run more by the medical schemes than by any other player in the market. There’s constantly a look at retail pharmacy in terms of, yeah, but that’s where most of the money goes – when in fact only about 13% if I remember the facts correctly goes to retail pharmacy. The rest goes to hospital specialists and doctors. So really, retail pharmacy isn’t a huge proportion of the medical budget.

There is of course the substitution of generic medications for originals that we’re compelled to offer to patients. The biggest problem there is that the medical aids are dictating pricing simply across the board.  So if a Discovery or a large medical scheme says, we’ll pay you the SEP (SEP being Single Exit Price) – so we don’t make a markup specifically on medicine.  Up until a value of about R150 we make 36%. Over and above that, we make a maximum depending on the medical aid scheme of R59 per item or R29 if it’s a lower medical scheme. So the margins are really not there in medication anymore because the medical aids dictate and because one large medical aid says this, then all the medical aids say that. We’re entitled to charge a significantly higher professional fee but in reality that really doesn’t happen in the cities because we need to compete with the Dis-Chems and the Clicks and the corporate pharmacies.

The Finance Ghost: Yeah, and hence the importance of that front shop model because it’s not just the additional sales and the additional margins but it’s also from a working capital perspective, someone pays you as they leave the shop, you’re not waiting 30 days to get paid. So these are all the joys of running a retailer. At the end of the day, it’s a tough business and I think retail pharmacy is a particularly tough business. But I guess that’s all part of why you went the franchise route at the end of the day. You mentioned it at the beginning, stuff like brand recognition, it just feels like it’s hard and if you go the franchise route, it takes away some of the difficulties, just one or two of them. The fact that someone says, oh, I’ve seen that brand before is now a trust thing, they at least say, well, I feel like I can trust this pharmacy. So I guess that’s part of it, right? It’s just de-risking the overall business. If you go the franchise route, you’re just taking some of the risk away, right?

Hugh Cunningham: Ghost, Absolutely. I can count on my colleagues within The Local Choice brand, no matter where they are, whether it be in Cape Town or Pofadder or Upington or wherever, to at least be giving a similar kind of level of service to what we give. And I think that’s what makes The Local Choice brand stand out is although we’re privately owned, I think because we’re privately owned, we all try and really give the kind of service that will keep people returning with an expectation of that level of service.

The Finance Ghost: Yep, that makes a lot of sense.  I think as we bring this discussion to a close – and I’ve really enjoyed actually understanding a little bit more about this segment of retail, I luckily do understand a little bit about it, I had some background knowledge coming in – but I remember when I first learned the things I learned about how independent pharmacies are managing to survive and how pharmacy licence access is a big part of that. Or actually, let’s touch on that quickly and then I’ll ask you the last question because we haven’t spoken about that. How hard is it to get a new pharmacy licence? Because my understanding is that a big part of how independents are surviving, is that there is actually a practical limit on how many pharmacy licences are given out to avoid a scenario where there’s destructive competition and pharmacies are failing because there are too many of them for the level of demand.

Hugh Cunningham: Ghost, I think that, yeah, the biggest problem is justifying how many feet or how many people would access that pharmacy in an area and trying to get a feel for that.  I think there’s a major problem in terms of shopping centres having two or even three corporate pharmacies within the shopping centre. That seems to be okay for corporates, but not so okay for private pharmacy.

The process of getting a licence is lengthy. It can take a year or more to actually get a licence approved and you have to submit plans.  They have to be architect-drawn plans to scale of the internals of the pharmacy. If you change the internals of the pharmacy, you have to re-apply, not for a licence, but you have to get the plans approved by Pharmacy Council. So any changes internally, you need to do a fair amount of work.

Fortunately, The Local Choice brand helps us in terms of those plans and submitting them to the Pharmacy Council. And they have a little bit of clout in terms of trying to get things ushered through a little bit quicker than normally would happen.

The Finance Ghost: Yeah, that makes sense. So now I can ask you the last question that I wanted to ask you, now that we’ve ticked that box off, which is just around your – and I ask all of my guests this question, I know it’s very cliche, but something interesting always comes out of it – which is just around your biggest mistake and thus learning along the way of this business.  What would you say that would be?

Hugh Cunningham: Yeah, difficult one. I think the big learning is to make sure that your staff are always happy and that they’re always abiding by the rules of pharmacy. And we have legislation probably second only to the finance industry in terms of what you can and can’t do. You’ve got to keep very strict control of what your staff is doing. You need to know what they’re doing so that they don’t make any mistakes.

And of course, mistakes are always made. It doesn’t matter what business you’re in. The only people who don’t make mistakes are those who don’t do any work! But you do need to try and pick those up as quickly as possible.  And if you do pick them up, address them with the patient as quickly as you can.

The Finance Ghost: Hugh, thanks. I think you’ve given us a lot of really good insights into the business, what it’s like to run essentially community specialist retail, which is a whole animal unto itself, really, and a very fascinating way to actually get up in the morning and run a business.  As a franchise as well, interesting realities of that and just tapping into that brand recognition and support and a network at the end of the day.

So thank you very much for your time on this podcast and hopefully listeners, next time they go to the pharmacy will maybe see their favourite pharmacy through new eyes. Look around you at what’s in the front shop. Think about how the business makes money. The fact that the dispensary is all the way at the back is not a mistake. It’s so that you walk past everything, I think, on your route to the dispensary and back again to the till so that you can hopefully shop in the front shop.

Because it’s a tough business – it’s actually quite a tough business and it’s an absolute necessity that we have pharmacies, so put something in your basket from the front shop of an independent pharmacy, go buy your gifts there, go buy what you can there, because it definitely helps to keep those businesses in your community.

Hugh Cunningham: Ghost, thank you very much for the opportunity. I would like to, just before the end, give a shout out to Capitec Bank, Capitec Business Bank, where we bank. We approached our previous bank for capital to grow. We had had an overdraft since 2009 and we asked for a little bit of an increase in the overdraft to grow and that was about two, three years ago. And they were so slow coming forward.

Capitec Business Bank came to the rescue. We’ve changed our account to Capitec Business Bank and we’ve been able to grow significantly since their contribution. So I’d like to make a shout out to Capitec Bank as well. The personal service there has been incredible. Thanks to you for this opportunity just to share a little bit of the background of retail pharmacy. I appreciate this time with you and you’ve asked some penetrating and interesting questions. Thank you so much.

The Finance Ghost: Thank you, Hugh. And it’s always nice to hear genuinely the Capitec clients just – it comes through so naturally, that you’re very happy with the service. I never have to say: “Oh, please tell us now all the lovely things about Capitec” – it’s actually a very sincere “Hey, these guys have really helped my business”. It came through 100% on the previous podcasts as well and it’s just lovely to see. I think it says a lot about the product that they are offering out there as well.

So well done, Capitec. Well done Hugh, good luck to you with your business journey.

Hugh Cunningham: Thank you so much. Appreciate that.

Real stories and real people. Yours could be next plugged in with Capitec. Capitec is an authorised financial services provider, FSP4 669.

Ghost Bites (Adcock Ingram | MAS | Newpark | SA Corporate Real Estate | Sappi)

Adcock Ingram shareholders give a resounding yes to the Natco Pharma deal (JSE: AIP)

No major surprises here

In July, Adcock Ingram announced that Natco Pharma wants to acquire all the outstanding shares in the company. The circular went out in early September and the shareholder meeting has now taken place. The deal was approved by 98.66% of shareholders in attendance.

I’m genuinely not sure what outcome the small number of dissenting shareholders were hoping for. The Natco Pharma offer of R75 per share is approximately 50% higher than where the share price was trading before the bid came to light, as shown on this chart:

There are still some outstanding conditions for the deal, but getting through the shareholder vote is a major milestone. The company will announce updated dates in due course.


A significant change of approach at MAS (JSE: MSP)

The new board is in no rush to pay dividends – or even to buy more properties!

With the dust having settled at MAS after a battle for control of the company, they’ve released an update to shareholders regarding the capital allocation plans going forwards.

Firstly, there are no guarantees that they will stick to Romanian real estate – or even real estate at all! The company is happy to move beyond the country and possibly even the sector, so that’s going to make it quite difficult for institutional investors to feel good about owning the shares. The individuals running the show at MAS are astute allocators, but that doesn’t mean that investors will be happy about a potential transition from property company to investment holding company. This is something to keep a close eye on, with MAS looking to sell properties that are expected to deliver lower returns than other opportunities.

On the balance sheet, MAS is repaying its 2026 bond ahead of schedule. The Development Joint Venture (DJV) has also redeemed €75.9 million of preferred equity, so cash has moved up the structure, but the DJV retains the right to recall this amount by notice.

Here’s another big change: the strategy is no longer focused on resuming dividend payments. Instead, MAS will look to optimise long-term shareholder value on a per share basis. This means share buybacks are much more likely than dividends.

There must be no shortage of churn on the shareholder register at the moment, as this is a huge change in strategic direction. MAS isn’t a REIT, so they aren’t forced to focus on dividends. They aren’t even forced to remain a property company!


Newpark REIT hit by negative reversions at the JSE building (JSE: NRL)

This is the problem with a highly concentrated portfolio

Most REITs on the market have a reasonable spread of properties in the portfolio, as the appeal for investors is that they can buy diversified property exposure. Newpark offers no such benefit unfortunately, with a portfolio of just four properties. This will soon be down to three properties, with the fund in the process of selling the property in Crown Mines.

This will leave them with two buildings in Sandton (the JSE and adjoining 24 Central) and a property in Linbro Business Park. Those Sandton properties might be iconic, but that doesn’t mean that Newpark has much negotiating power.

When a lease has been running for many years with escalations above market levels, then the expiry of that lease is an opportunity for the tenant to bring things back down to earth. That’s unhappy news for the landlord of course. This is exactly what happened at the JSE building, which is why Newpark’s results for the six months to August look so poor.

Revenue dipped 7.3% and funds from operations per share tanked by 24.5%. The loan-to-value ratio has increased from 43.1% to 44.5%. The good news is that at least the weighted average cost of debt has come down nicely from 9.3% to 8.9%.

The interim dividend of 26 cents per share is 13.3% lower than the prior year.

In terms of the outlook, the company originally expected funds from operations per share to be between 39 and 46 cents for the year ending February 2026. They’ve revised this higher to between 41.50 and 48.50 cents.

There’s just about no liquidity in the shares, so this is most useful as a cautionary tale around concentrated portfolios and the risk of negative reversions.


SA Corporate Real Estate is keen to own more residential property (JSE: SAC)

This is buy-to-let at scale

Residential property isn’t a popular choice among REITs. They far prefer owning shopping centres and industrial properties, while trying to do the best they can with problematic office portfolios. At SA Corporate Real Estate though, they are no strangers to residential property or the resilient underpin that this asset class can provide when you have a large enough portfolio of apartments.

The residential investments are typically made through Adhco Holdings, so SA Corporate has a dedicated structure in place for them. The latest deal is the acquisition of Parks Lifestyle Apartments at Riversands for R1.68 billion. Talk about buy-to-let at scale!

The development is near Steyn City and comprises 1,960 residential units from bachelor to three-bedroom apartments. R31 million of the purchase price is deferred until the final block of 40 units is built, taking the total development to a juicy 2,000 units.

The plan at SA Corporate is usually to buy large portfolios and then drip feed them into the market while earning rentals on the remaining properties. They believe that they can offload these units at yields under 8% and they can sell other residential units within the broader residential portfolio for yields under 8.5%.

Or, put differently, buying residential apartments is a really bad investment when you buy just one apartment, but it’s not bad if you can get your hands on them in bulk and then sell them off slowly.

Even then, the net operating income on this portfolio is expected to be R159.6 million in the year ending December 2026. That’s a forward yield of 9.5%. Once you take off the expected cost of debt, the expected profit before tax is R80.5 million. They are expecting to do the deal on a loan-to-value ratio of 57%, so the equity outlay is R719 million. This means an expected return on equity in 2026 of 11.2% excluding the benefit of selling any of the units.

As you can see, the returns on residential property aren’t amazing even when you can do deals at this scale. The problem is that property prices in Joburg show very little capital growth, so investors are reliant on yields. But with the market happily buying SA Corporate Real Estate shares on a yield of just 7.5%, they can do deals like these to create shareholder value.


Facing a perfect storm for the balance sheet, Sappi is digging for every coin between the couch cushions (JSE: SAP)

You won’t be seeing a dividend this year

Sappi’s share price is down a rather spectacular 56% year-to-date. You know it’s bad when you would’ve been better off buying a new car on 1 January than buying shares in Sappi. At least you can drive the rapidly depreciating car, which is a lot more fun than watching your Sappi position implode.

In a situation that isn’t unfamiliar to regular readers, we have a classic case of a company that ran the balance sheet too hot before the market washed away from them. This often leads to a rights issue to plug a hole in the balance sheet, as we saw recently at the likes of Gemfields (JSE: GML). Although Sappi doesn’t make mention of the words “rights issue” (companies rarely do unless they are out of options), they are certainly doing everything possible to avoid landing up in that situation.

They have a few obvious levers to pull, like suspending the dividend for FY25. They’ve also adjusted their capital expenditure for the next two years, with no expansionary capex planned. That makes sense, as expanding into a weak market doesn’t seem smart.

It’s a good start, but the real key is having the support of the banks. Sappi has access to $800 million through existing cash and revolving credit facilities, but debt covenants are a problem because of the poor operating environment and its effect on earnings. The banks have agreed to increase the leverage covenant levels for the next year, so that’s a temporary solution. Sappi is also looking to extend the revolving credit facilities and to “term-out” a portion of debt with a new 5-year term facility.

The share price closed 5% higher on the day, so the market appreciates the efforts. Still, it takes a brave soul to buy this chart:


Nibbles:

  • Director dealings:
    • Jan Potgieter, the ex-CEO of Italtile (JSE: ITE), sold shares worth R4.6 million. His long journey with the company has come to an end as he is also leaving the board, so I’m not overly surprised to see some share sales from him.
    • The CEO of ADvTECH’s (JSE: ADH) resourcing business sold shares in the group worth R3.4 million.
    • The company secretary of Growthpoint (JSE: GRT) sold shares worth R1.6 million.
    • Des de Beer is back at it with Lighthouse Properties (JSE: LTE), buying shares worth R1.4 million.
  • Harmony Gold’s (JSE: HAR) acquisition of MAC Copper in Australia has become legally effective, which means that Harmony will be the proud owner of the mine with effect from 24 October.
  • Back in February 2025, Merafe (JSE: MRF) announced that its joint venture with Glencore (JSE: GLN) had entered into an enhancement under the legacy agreement with Sibanye-Stillwater (JSE: SSW). The plan was to accelerate the delivery of contracted chrome volumes and for the joint venture to take operational control of the majority of chrome recovery plants at Sibanye’s local PGM operations. The latest update is that the Competition Tribunal has granted unconditional approval to the consolidation of management of various plants that are currently separately owned and operated by the joint venture and Sibanye.
  • Standard Bank (JSE: SBK) confirmed that the SARB’s Prudential Authority has approved the appointment of David Hodnett as the CEO of Standard Bank South Africa. His appointment is therefore effective 10 October 2025 i.e. immediately.
  • The format of disclosure on the Australian Stock Exchange means that it isn’t the easiest thing to follow the details of the current capital raising efforts at Orion Minerals (JSE: ORN). The company has issued A$1.26 million in shares and has secured further commitments for A$4.4 million. But if you go back a couple of announcements, they previously indicated that the raise had been increased to $8.6 million, so I presume that this is still the total planned amount. Just to add an additional announcement into the mix, the company confirmed that Ratel Growth, which currently has an 8.3% stake in the company, acquired additional shares for A$2 million. I can only assume that this is part of the capital raise.
  • Mondi (JSE: MNP) announced the results of the dividend reinvestment plan. Across the UK and South African share registers, holders of a total of 4.26% of shares in Mondi elected to reinvest the dividend. When you consider how severely the share price has dropped, it’s quite amazing that more holders didn’t choose to average down at these levels and reinvest their dividends.

Port Royal: the city that sank for its sins

Before there was Las Vegas, there was Port Royal: a city of pirates, plunder, and peril clinging to the southern edge of Jamaica. The 17th-century hotspot was once the beating, drunken heart of the Caribbean, until one Sunday in 1692, when the earth opened up and swallowed it whole (quite literally). There’s more truth to Disney’s tales of Captain Jack Sparrow than you might realise.

By the late 1600s, Port Royal was considered to be the crown jewel of the Caribbean – although on second thoughts, “crown” may be a bit too generous a description. In reality, Port Royal was probably more like a golden tooth: gleaming, ostentatious, and clearly quite rotten.

Founded by the Spanish in 1494, Port Royal officially became a British outpost after the Brits wrestled Jamaica from Spanish hands. Its location at the mouth of Kingston Harbour, smack in the middle of Spanish-controlled seas, made it the perfect launchpad for privateers.

Privateers were essentially pirates on the British payroll. They were legally allowed to rob Spanish ships on behalf of the British Crown, which made them both criminals and civil servants, depending on the week’s foreign policy. When England and Spain were at war, the privateers were “heroic seamen”. When peace between the two countries returned, they were downgraded back to pirates, or simply thieves with boats.

Still, privateering was a profitable arrangement. Gold and silver from Spanish galleons poured into Port Royal like rain, and soon the place was booming. In its absolute heyday, it had a population of almost 8,000, and that population sure liked to party. In July 1661 alone, 40 licenses were granted to open new taverns. By 1662, Port Royal was recorded as having one tavern for every ten residents.

Sin City by the sea

If you squinted, Port Royal looked a bit like London, with its narrow cobble streets, brick-and-wood houses, busy merchants, and the occasional pickpocket. But the similarities stopped there.

This was the kind of town where morality was the exception, not the norm. Public drunkenness was normal, gambling was a civic pastime, and prostitution wasn’t just tolerated, it was practically part of the tourism industry. Sailors fresh off the high seas filled the taverns, flinging coins and curses in equal measure. There were carpenters and cobblers, shipwrights and blacksmiths, all feeding off the booming pirate economy. Money sloshed through the streets as freely as the rum, and few cared to question where it all came from.

The key to Port Royal’s popularity was its exceptionally deep harbour, which allowed up to 500 ships to dock at once. This meant constant trade and an equally constant influx of trouble. The city was built, quite literally, on sand – a fragile spit of land that jutted out into the Caribbean. Geographically, it was a risky position, but no one seemed to worry about geology when the economy was this good. As the population grew, more land was laid dry to make space for new buildings. The pirates were essentially stealing territory from the sea itself.

To the devout back in England, Port Royal was less a colony and more a cautionary tale; a sun-drenched Babylon in the tropics. Clergymen called it “the wickedest city on earth.” And like any good biblical story, the ending would be apocalyptic.

June 7, 1692

It was a Sunday morning, just before noon. The markets were busy, the taverns already humming, and the church bells likely ringing with irony. Then the ground began to shake.

At first, people thought it was a passing tremor. But within seconds, the shaking turned violent. Brick walls cracked, the church tower crumbled, and the harbour churned like a pot of boiling stew.

Modern geologists estimate it was a magnitude 7.7 earthquake that struck not just Port Royal, but the whole of Jamaica. That’s an enormous force unleashed directly beneath a city built on sand. And that sand was about to betray them.

When earthquakes hit sandy soil, an eerie process called liquefaction happens. The solid ground suddenly behaves like water, and everything sitting on it begins to sink. The ground that Port Royal was built on didn’t crack or heave during the earthquake – it essentially liquified. Two-thirds of the city slid straight down into the sea. Buildings vanished whole. Streets folded in on themselves. People, animals, and homes were all pulled under in a matter of minutes.

For a city long accused of sin, it was the most literal form of damnation imaginable. But the earthquake was just Act One.

Moments after the ground stopped shaking, the sea struck back. The shifting seabed had triggered a tsunami, or more precisely, what scientists call a “seiche wave”. The harbour turned into a giant sloshing bowl, with water surging back and forth, smashing ships against each other and flinging them inland. One British vessel, the HMS Swan, was hurled across the city and deposited inside a house. This impossible image was confirmed by archaeologists centuries later when they found the ship’s hull still lodged in the building’s ruins.

In the space of minutes, Port Royal was unmade through an almost biblical trifecta of earthquake, liquefaction, and tsunami.

A city cursed twice

The survivors, which numbered around 4,000 immediately after the earthquake, stumbled through a landscape that barely resembled the city they knew. Half of Port Royal was at the bottom of the sea, and what was left on land was reduced to rubble.

Wells were contaminated, food quickly ran out, and disease swept through the survivors. Within weeks, another 2,000 had died from injuries, infection, or thirst. To the British back home, the disaster was divine justice. Pamphlets declared the city’s destruction proof of God’s wrath. It was a convenient narrative – sin, punishment, lesson learned – but it ignored the geological explanation. The city had been built in exactly the wrong place, on a sandbar barely holding itself together. And when nature pushed back, there was nothing man, government or pirate could do to stop it.

When money trumps sense

Today, Port Royal is a treasure trove for archaeologists, a kind of Caribbean Atlantis that tells its story brick by perfectly preserved brick.

Modern dives have mapped entire blocks of the old city, revealing homes, shops, and even the remnants of Fort James. Artifacts like coins, pipes, pottery and even sealed bottles of wine can be found in the remnants of eerie underwater buildings. The city that once epitomised greed and excess now lies in perfect silence, inhabited only by fish. Above it, ships still glide into Kingston Harbour, probably unaware that beneath their hulls lies a city once called “the richest and wickedest on earth.”

If there’s a lesson in Port Royal’s story, it’s not the one preached by the moralists of 1692. It’s simpler and far more human. Every civilisation has its Port Royal moment – that point where success turns into overconfidence and growth outpaces good sense. The pirates in this story just happened to build theirs on sand.

Three hundred years later, as coastal cities expand into floodplains and developers pave over wetlands, Port Royal’s story feels less like ancient history and more like a prophecy. As modern skylines rise higher, it’s worth remembering that nature has never needed a sermon to deliver a reckoning.

About the author: Dominique Olivier

Dominique Olivier is the founder of human.writer, where she uses her love of storytelling and ideation to help brands solve problems.

She is a weekly columnist in Ghost Mail and collaborates with The Finance Ghost on Ghost Mail Weekender, a Sunday publication designed to help you be more interesting. She now also writes a regular column for Daily Maverick.

Dominique can be reached on LinkedIn here.

Ghost Bites (Deneb | Discovery | Equites Property Fund | Hammerson | Pick n Pay)

Deneb is acquiring 80% in Dawning Filters (JSE: DNB)

This is a very good example of the types of deals and pricing you see locally

Deneb is involved in the manufacturing and distribution of industrial products. As is typical for companies in this space, they are open to acquisitions to expand the overall product offering.

As the name suggests, Dawning Filters supplies all kinds of filtration products to customers across multiple industries. The company has distribution offices in Joburg, Durban and Cape Town, with manufacturing done in Durban.

Deneb is paying R80 million for an 80% stake in the company, so you don’t need to get the calculator out to know that the implied value of the entire company is R100 million. Profit after tax for the year ended February 2025 was R15.7 million, so the earnings multiple is 6.4x.

Importantly, there’s a pathway to a 100% stake in the form of a put option that becomes exercisable after four years for a six-month window period. But there’s no call option, so Deneb cannot force the issue to get to 100% – the sale of the final 20% is at the option of the sellers of the business. The maximum consideration that could be payable to the sellers is R120 million, so Deneb has wisely included a cap on the option. The basis of the calculation for the put option price is 6x average annual profit.

This is a category 2 transaction, so Deneb shareholders won’t be voting on it. There are various other conditions though, so it will no doubt take a few months to close the deal.


Discovery’s financial year is off to a good start (JSE: DSY)

The medium-term plan calls for mid-teens growth

Discovery presented at the UBS South Africa Financial Services Conference this week. Hylton Kallner, CEO of Discovery South Africa and Discovery Bank, led the presentation. I think it’s fairly obvious how the succession planning is shaping up at Discovery. You’ll find the presentation here.

The group had a very strong FY25 and took the opportunity to remind attendees that normalised headline earnings increased 30%. That’s always a nice way to set the scene!

There’s a very cheeky slide in which they talk about Discovery being number 1 in every category they play in locally. But the metric changes each time e.g. for Discovery Life they use market share and for Discovery Bank they use “number 1 bank brand” – market share is what counts, in which case they are very far from being number 1 across a couple of verticals. I’m not sure why they dilute such an objectively excellent year with such an obviously skewed way of explaining their market positioning:

There are also some very interesting slides on the data they have on things like sleep duration and how this affects health and overall risk of vehicle accidents etc. This is of course the Vitality data that they’ve been building for years now, with the AI era making it even more powerful (and valuable) than before.

The five-year growth ambition for the group is a CAGR of 15% to 20% in profit from operations. Although the South African business is the most mature part of the group, they expect it to achieve a CAGR of 12.5% to 17.5%. Yes, the ecosystem will need to work very well for this to be achieved, but they are firmly on that path.

The presentation also included an update on trading for the first quarter of the new financial year. They are calling it a strong start, with decent new business growth numbers and favourable claims and persistency experiences vs. embedded value expectations (that’s good for profits).

The share price went through a significant recent sell-off, but seems to have positive momentum once more.


Equites Property Fund remains far more bullish on SA than the UK (JSE: EQU)

That’s just as well, as they’ve taken significant steps to bring capital home

Equites Property Fund released results for the six months to August. The narrative tells a more positive story about South Africa, although they note that a “broad-based recovery has yet to take place” despite the recent optimism. That’s a lot better than the UK, with 10-year gilt yields (government bonds in the UK) at historically high levels and the UK logistics property market stuck in a state of low growth.

Equites has made it clear that they are reallocating capital from the UK to South Africa and they’ve already done some significant transactions to make that happen. The narrative simply confirms that nothing has changed regarding that strategy.

For the interim period, like-for-like portfolio rental growth was 5.1% and valuations were up 4.0%, so that’s a solid combination. The loan-to-value ratio did come in a bit higher at 37.2% (vs. 36.0% in February 2025), but the all-in cost of debt thankfully dropped by more than 50 basis points to 8.3%.

The dividend per share was 3.8% higher, while distribution guidance for the full year has been reaffirmed at growth of between 5% and 7%.

The net asset value (NAV) is R16.93 and shares are currently trading at R16.05. The entire sector has seen a reduction in discount to NAV as prospects have improved.


Hammerson is enjoying decent momentum (JSE: HMN)

A ratings agency upgrade does wonders for debt costs and availability

UK property fund Hammerson had no trouble with a €350 million bond issuance that was 5 times oversubscribed. This issuance is part of the refinancing of the €700 million bonds maturing in 2027. It helps that Fitch upgraded the company’s unsecured debt rating and Moody’s revised the rating to a positive outlook.

Due to the timing of the bond issuance, they now expect full year earnings to be £101 million, ever so slightly down from previous guidance of £102 million.

The announcement also includes a trading update based on the summer months, where UK and French footfall were up by mid-single digits. As one would hope, properties that went through significant redevelopment and repositioning did particularly well. Importantly, they are achieving a significant rent increase in long-term lease agreements.


Pick n Pay’s like-for-like momentum is encouraging, but the group is still making losses (JSE: PIK)

Retail turnarounds are hard

Pick n Pay released a trading statement for the 26 weeks to August 2025. The group is unfortunately still loss-making, so we may as well get that out of the way. The headline loss per share has improved by between 50% and 60%, but it’s still a loss of between -54.31 cents and -67.97 cents. In absolute terms, the headline loss is between -R399 million and -R479 million.

So, there’s a long way to go. The key metric to watch is like-for-like growth in Pick n Pay SA, where they came in at 4.3% for the interim period vs. 3.6% in the 17 weeks to 29 June 2025 (in other words there was a strong acceleration towards the end of the period). In the previous interim period, they only grew 1.1%, so this is a significant improvement.

The franchise supermarkets have been a tough story. They are still lagging, with growth of 1.7% vs. company-owned supermarkets at 4.8%. Franchise also had a really easy base in this period, as the comparable period was a like-for-like decrease of -1.4%!

Clothing standalone stores were up 7.5%, with a soft base effect here as well thanks to growth of just 0.2% in the comparable period.

Total turnover growth for Pick n Pay is below like-for-like growth as they’ve been reducing the store footprint to try and shrink into profitability. This has dire long-term consequences, with key rival Shoprite (JSE: SHP) happily mopping up those sites and increasing their footprint. It’s also clear that Boxer (JSE: BOX) is still by far the best business in the Pick n Pay group.

The Pick n Pay share price remains in the red this year, reflecting how hard a turnaround actually is.


Nibbles:

  • Director dealings:
    • Three directors of Hyprop (JSE: HYP) have sold shares worth a total of R14.6 million. The announcement notes that this is the first sale in several years and that this is to rebalance portfolio exposures. The company also has minimum shareholding requirements in place for executives. Fair enough then.
    • A director of a major subsidiary of AVI (JSE: AVI) received share awards and sold the whole lot to the value of just over R6 million. The company secretary of the listed holding company received awards and also sold all of them, with a total value of nearly R5.8 million.
    • The financial director of Pan African Resources (JSE: PAN) bought shares worth R425k. That’s interesting timing, as the gold price is looking pretty spicy at the moment!
    • Although Impala Platinum (JSE: IMP) announced dealings by many directors in relation to share awards, I don’t think there was enough of a pattern for us to really read anything into it. Thanks to the recent run in the PGM sector, the share awards ended up being worth meaty numbers for the execs!
  • Schroder European Real Estate (JSE: SCD) has had a rough year in its share price and the recent valuation trend won’t do much to improve that. In the quarter ended September, the total portfolio value was up just 0.1% quarter-on-quarter. As you would expect, there are bigger swings at individual property level, mostly driven by the passage of time on existing leases and thus the changes to lease terms.
  • After Silchester International Investors had lots to say in the media about the Barloworld (JSE: BAW) offer and the price they would be willing to accept, it turns out that they’ve now disposed of their entire holding in the company. So much for “at least R130 per share” then.
  • City Lodge (JSE: CLH) announced that Entertainment Holdings and Tsogo Sun Investments – part of Tsogo Sun (JSE: TSG) – sold shares in City Lodge such that they now hold just 3%. Tsogo had a stake of over 10% that was acquired in 2023, so that’s a particularly interesting move.
  • In August, Mahube Infrastructure (JSE: MHB) released a cautionary announcement regarding a potential buyout offer for the company by an existing shareholder. The company has renewed the cautionary announcement, as engagement between the independent board and the potential offeror is continuing. As this stage, there’s no firm intention to make an offer, so caution really is warranted here.
  • Dr Leila Fourie is retiring as CEO of the JSE (JSE: JSE) at the end of March 2026, having been in the role since 2019. Valdene Reddy, currently the Director of Capital Markets at the JSE, has been named as Fourie’s successor.
  • BHP (JSE: BHG) investors didn’t exactly form an orderly queue for the dividend reinvestment plan. Holders of less than 4% of total shares in issue elected to participate, with the rest happy to receive cash.
  • Metrofile (JSE: MFL) announced that there are no longer any put or call option arrangements between Sabvest (JSE: SBP) and an associate of director Phumzile Langeni in relation to the company’s shares. It doesn’t seem like any dealings in shares happened as part of this.
  • Labat (JSE: LAB) renewed the cautionary announcement regarding the potential disposal of certain subsidiaries to All Trading. Negotiations are ongoing.

Who’s doing what this week in the South African M&A space?

0

Growthpoint Properties subsidiary, Growthpoint Healthcare Properties (GHPH), which is managed by Growthpoint Investment Partners, is to acquire the properties and operations of Auria Senior Living, a developer, owner and operator of senior living communities in South Africa. The property assets are valued at R2,4 billion and would initially add four Auria senior living communities to the portfolio. Auria will continue to operate under its current leadership team and brand. Auria’s pipeline of developments include Coral Cove in Salt Rock, KZN in addition to brownfield opportunities which GHPH intends to commence. The acquisition will take GHPH’s assets under management to c.R6,2 billion.

Kibo Energy has announced it will potentially acquire Carbon Resilience, a utility-scale industrial decarbonisation and renewable energy company for US$135 million (R2,3 billion) from FA SPC Real Asset Income, part of the institutional asset management platform of the ARIA Commodities’ group. Following the completion of a due diligence process, the company will be required to undertake a fundraising in connection with the transaction. Kibo will issue c.966 million ordinary shares at an issue price of 10.4 pence per share and will seek shareholder approval for a 1,600:1 share consolidation. The transaction will result in a reverse takeover of the company.

SA Corporate Real Estate (SAC) through its wholly-owned subsidiary SA Retail Properties, has entered into an agreement with Tinos Consulting and Advisory to dispose of Bluff Towers Shopping Centre in Durban for a cash consideration of R544,65 million. The disposal aligns with SAC’s strategy of reducing its retail exposure to KZN.

Vunani’s 78% held subsidiary Vunani Fund Manager has acquired the remaining shares in Sentio Capital Management – a black-owned and managed fund manager. Prior to the merger, Investment Managers Group (IMG) held a 30.05% stake in Sentio. Due to the dilution of its stake as a result of the merger, IMG opted to exit its stake as part of concluding the merger. Sentio will be merged with VFM to form Vunani Sentio Fund Managers. VFM will issue 44,754 shares to Sentio’s shareholders and a cash consideration.

Deneb Investments will acquire 80% of issued share capital of Dawning Filters from vendors MG Dain and the Dibb Family Trust. The R80 million purchase consideration will be paid in cash to the sellers in a 50:50 ratio. The deal is a category 2 transaction and as such does not require shareholder approval.

On 1 October 2025, the parties to the Barloworld transaction agreed to waive the Standby Offer Condition relating to the receipt of competition regulatory approval by COMESA. As at 6 October 2025, NewCo had received valid acceptances of the Standby Offer in respect of 108,25 million shares equating to c.58% of shares in issue. This combined with the Consortium’s and Barloworld Foundation shares equates to 81.8% of the shares in issue. Shareholders who still wish to accept the Standby Offer have until Friday, 7 November 2025 to do so. Results will be announced on 10 November 2025.

36ONE Asset Management has concluded a BEE transaction with a consortium led by MI Capital and including 36ONE staff members and youth communities represented through the Invincible Empowerment Trust. The consortium will acquire a 22% stake in the company. Financial details were not disclosed.

Dibber International Preschools has acquired the South African LittleHill Montessori group of schools, which include five campuses in Kikuyu, The Polofields, Fynbos, Thaba-Eco, and The Huntsman. The five schools will now operate under the Dibber Montessori name, continuing their strong Montessori focus while incorporating Dibber’s Nordic pedagogy, which emphasises play-based learning and holistic child development. Financial details undisclosed.

EduLife, a South African network of private schools, has acquired Arrow Academy, marking the scaling of it footprint into Gauteng. The expansion was supported by Sanari Capital’s 3S Growth Fund, under which EduLife is a portfolio company. Financial details were undisclosed.

Weekly corporate finance activity by SA exchange-listed companies

0

Optasia, a fintech company in which Ethos Capital holds an indirect interest, has announced plans to list on the JSE, raising up to R6,3 billion by selling a combination of new and existing shares. Optasia’s AI-driven platform makes credit-vetting decisions by analysing various unstructured data sets. It works closely with mobile network operators, mobile wallet operators and financial institutions thereby unlocking financial opportunities for the underbanked across emerging markets. Optasia has c. 121 million monthly active users, processing over 32 million loan transactions per day with access to over 860 million mobile subscribers though its distribution partners and financial institutions.

Orion Minerals has again increased the size of its capital raise this time to A$8,6 million (R99 million) – initially the company announced a A$5 million capital raising exercise but increased this to A$7,7 million due to level of demand. The private placement now comprises the issue of c. 574 million shares at an issue price of 1,5 cents (R0.17) per share.

Visual International has launched an equity raise of up to R2 million though the issue of new ordinary shares implemented through an accelerated bookbuild process. Funds will be used to assist with the company’s working capital requirements.

Marshall Monteagle plc will launch the renounceable Rights Offer to raise up to US$10,7 million from shareholders in terms of which a total of 8,964,377 Rights Offer shares will be offered at an issue price or $1.20 per share in the ratio of one Rights Offer share for every four Marshall shares. The maximum number of shares that can be issued in terms of the Warrants is 4,482,188 and the maximum amount raised $5,3 million.

BHP has purchased 3,997,199 shares, valued at c. R11,86 billion, in terms of its Dividend Reinvestment Plan for those shareholders electing to have shares allocated to them in lieu of the final 2025 cash dividend.

Remgro has received South African Reserve Bank approval for the payment of a gross special dividend to shareholders of 200c per ordinary share.

Last week, the JSE informed Labat Africa shareholders that the company had failed to submit its annual report timeously and its shares were under threat of suspension. Labat has advised that new accountants have been appointed and that it will publish the annual financial statements for the year ended May 2025 by 15 October 2025.

This week the following companies announced the repurchase of shares:

Old Mutual is the latest company to implement a share repurchase programme. It will repurchase c.220 million ordinary shares for a total consideration of R3 billion. The repurchase will take place on the JSE only and the shares will be cancelled reverting to authorised but unissued ordinary share capital.

Over the period 30 September to 3 October 2025, eMedia repurchased 15,327,677 N ordinary shares representing 3.44% of the companies issued share capital. The shares were repurchased for an aggregate R27,77 million using cash resources.

City Lodge Hotels repurchased 42,729,300 shares over the period 10 March 2025 to 3 October 2025. The shares, which have been delisted and cancelled, were acquired at an average price of R3.99 per share for an aggregate value of R170,29 million. The general repurchase was funded from available cash resources and debt facilities.

South32 continued with its US$200 million repurchase programme announced in August 2024. The shares will be repurchased over the period 12 September 2025 to 11 September 2026. This week 784,611 shares were repurchased for an aggregate cost of A$2,23 million.

On March 6, 2025, Ninety One plc announced that it would undertake a repurchase programme of up to £30 million. The shares will be purchased on the open market and cancelled to reduce the Company’s ordinary share capital. This week the company repurchased a further 31,526 ordinary shares at an average price 204 pence for an aggregate £64,398.

The purpose of Bytes Technology’s share repurchase programme, of up to a maximum aggregate consideration of £25 million, is to reduce Bytes’ share capital. This week 489,711 shares were repurchased at an average price per share of £3.98 for an aggregate £1,95 million.

Glencore plc’s current share buy-back programme plans to acquire shares of an aggregate value of up to US$1 billion. The shares will be repurchased on the LSE, BATS, Chi-X and Aquis exchanges and is expected to be completed in February 2026. This week 7,200,000 shares were repurchased at an average price of £3.44 per share for an aggregate £24,79 million.

In May 2025, British American Tobacco plc extended its share buyback programme by a further £200 million, taking the total amount to be repurchased by 31 December 2025 to £1,1 billion. The extended programme is being funded using the net proceeds of the block trade of shares in ITC to institutional investors. This week the company repurchased a further 912,826 shares at an average price of £38.34 per share for an aggregate £35 million.

During the period 29 September to 3 October 2025, Prosus repurchased a further 1,479,279 Prosus shares for an aggregate €89,55 million and Naspers, a further 247,516 Naspers shares for a total consideration of R319,78 million.

Two companies issued profit warnings this week: Newpark REIT and Pick n Pay.

During the week five companies issued or withdrew a cautionary notice: MTN Zakhele Futhi, Vunani, Conduit Capital, Mahube Infrastructure and Labat Africa.

Who’s doing what in the African M&A and debt financing space?

0

Gabonese startup, POZI, has closed a €650,000 fundraising round led by Saviu Ventures, with participation by Emsy Capital and Chazai Wamba. POZI specialises in telematics and fleet management. Using data and artificial intelligence, the platform provides managers, insurers, and institutions with predictive analytics to anticipate breakdowns and incidents, real-time performance indicators to manage their operations, and risk management solutions tailored to African realities.

Barrick Gold, a Canadian-based global mining company, has announced the sale of its interests in the Tongon gold mine and certain of its exploration properties in Côte d’lvoire to the Atlantic Group for total consideration of up to US$305 million. Owned by an Ivorian entrepreneur, Atlantic is a leading privately held multisectoral Pan-African Group with diversified interests in financial services, agriculture, and industry, and a strong footprint across 15 countries in Africa.

Inspired Evolution’s Evolution III Fund, a fund dedicated to next-generation energy transition, has committed US$20 million to Cold Solutions East Africa Holdings (CSEAHL), a temperature-controlled warehousing and logistics platform operating across Kenya, Uganda, Rwanda, and Tanzania. The investment will support the development and construction of modern cold-chain infrastructure throughout East Africa, helping to reduce post-harvest losses, strengthen food systems, enhance food security, and drive energy and resource-efficient growth in the region.

To help improve access to clean and affordable water in Sierra Leone, Zvilo Africa, a working capital lender, has partnered with So Pure to support the scale of treatment and distribution of safe drinking water across the West African country. So Pure targets low-income and middle-class households across Sierra Leone with clean water, handling every step of the supply chain: purifying the water, packaging it into half-litre sachets or large dispenser 20-litre bottles, and then distributing it to mom-and-pop kiosk shops across the Freetown region. Since 2019, the company has focused on water purification and filling up sachets sourced from a range of local packaging suppliers. An expansion phase aims to distribute 10-12 million litres of purified drinking water monthly by year-end, helping provide clean, safe and affordable drinking water to over 500,000 people.

French long-term infrastructure and impact investor, STOA, has made a US$27 million equity investment into Atlas Tower Kenya (ATK). Backed by Kalahari Capital, Atlas Tower Kenya owns and operates more than 450 telecom towers nationwide, providing critical digital infrastructure that enables mobile network operators to deliver reliable and ubiquitous connectivity. ATK has been operating in Kenya since 2019 with a blended mix of sites in urban, rural, and underserved communities.

Zambian integrated poultry producer, Hybrid, has received a debt investment from specialist impact investors, AgDevCo. The investment, a US$10 million senior debt loan, will enable Hybrid to increase its processing capacity by building a modern abattoir which will create 270 jobs and support the company’s growth.

Tagaddod, an Egyptian tech-powered renewable feedstocks platform, has closed a US$26,3 million Series A led by The Arab Energy Fund, with support from existing investors FMO, Verod-Kepple Africa Ventures and A15 Ventures. Tagaddod has developed a proprietary, tech-powered platform that collects, aggregates, and traces renewable waste-based feedstocks from thousands of suppliers, including households, restaurants, food manufacturers, and collectors across its operating markets.

Ellah Lakes an integrated agro-industrial company in Nigeria,has announced that it has entered into an agreement for the acquisition of 100% of Agro-Allied Resources & Processing from ARPN PTE, Singapore. ARPN PTE. is equally owned by Tolaram Africa PTE Ltd and Valuestar Holdings PTE. The acquired assets comprise 11,783 hectares of cultivated land (planting over 6,280 hectares of oil palm plantations and associated infrastructure), 2,093 hectares of cassava plantations land and an additional 10,393 hectares of uncultivated land. Financial terms were not disclosed.

Verified by MonsterInsights